



Trends in kinase drug discovery: targets, indications and inhibitor design

Misty M. Attwood¹, Doriano Fabbro², Aleksandr V. Sokolov¹, Stefan Knapp^{3,4,5} and Helgi B. Schiöth^{1,6}✉

Abstract | The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology area and beyond. Twenty years on, this article analyses the landscape of approved and investigational therapies that target kinases and trends within it, including the most popular targets of kinase inhibitors and their expanding range of indications. There are currently 71 small-molecule kinase inhibitors (SMKIs) approved by the FDA and an additional 16 SMKIs approved by other regulatory agencies. Although oncology is still the predominant area for their application, there have been important approvals for indications such as rheumatoid arthritis, and one-third of the SMKIs in clinical development address disorders beyond oncology. Information on clinical trials of SMKIs reveals that approximately 110 novel kinases are currently being explored as targets, which together with the approximately 45 targets of approved kinase inhibitors represent only about 30% of the human kinome, indicating that there are still substantial unexplored opportunities for this drug class. We also discuss trends in kinase inhibitor design, including the development of allosteric and covalent inhibitors, bifunctional inhibitors and chemical degraders.

¹Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden.

²Cellestia Biotech, Basel, Switzerland.

³Structural Genomics Consortium, Goethe University Frankfurt, Buchmann Institute for Molecular Life Sciences, Frankfurt am Main, Germany.

⁴Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt am Main, Germany.

⁵German Cancer network DTK and Frankfurt Cancer Institute (FCI), Goethe University Frankfurt, Frankfurt am Main, Germany.

⁶Institute for Translational Medicine and Biotechnology, Sechenov First Moscow State Medical University, Moscow, Russia.

✉e-mail: helgi.schioth@neuro.uu.se
<https://doi.org/10.1038/s41573-021-00252-y>

Reversible protein phosphorylation mediated by kinases and phosphatases has a key role in regulating cellular functions such as cell proliferation, apoptosis, subcellular translocation, inflammation and metabolism^{1,2}. The human kinome is composed of around 560 protein kinases, including approximately 500 eukaryotic protein kinases (ePKs) that are divided into eight major groups, such as tyrosine kinases, and approximately 60 atypical protein kinases, such as lipid kinases, which have a conserved kinase fold like ePKs but differ with regard to other highly conserved sequence motifs of ePKs^{3,4}.

Since the 1980s, protein kinases have been recognized as potential drug targets, particularly based on advances in the molecular understanding of cancer, including the discovery of oncogenes such as SRC⁵. However, the development of protein kinase inhibitors that bind to the ATP site was initially viewed as an unsurmountable challenge because of the high concentration of ATP in the cell, the poor understanding of the regulation of kinase activity and the conserved ATP-binding pocket. Nevertheless, the natural compound staurosporine⁶ was pursued because it had potent kinase inhibitory activities, albeit with poor selectivity. By the end of the 1980s, this paved the way to identify and optimize synthetic small-molecule kinase inhibitors (SMKIs) directed at the ATP-binding site with suitable drug-like properties, selectivity and potency^{7–9}.

In parallel with such efforts in the 1990s, two kinase inhibitors received regulatory approval. Fasudil, an inhibitor of Rho-associated coiled-coil-containing protein kinases 1 and 2 (ROCK1 and ROCK2) was approved in Japan in 1995 for the treatment of cerebral vasospasm, although the ROCK-inhibitory activity of fasudil was not described until 1997. Sirolimus, a natural product that had a key role in the discovery of mechanistic target of rapamycin (mTOR)^{10–13}, became the first kinase inhibitor to reach the market in the United States in 1999, when it was approved by the FDA for the prevention of organ rejection¹⁴, and, in retrospect, was the first allosteric kinase inhibitor. Given the history of these two drugs, imatinib (CGP 57148, STI571) — which was discovered in the labs of Ciba-Geigy in 1992 (REF.¹⁵) and approved by the FDA in 2001 — is perceived as a pivotal landmark in the development of kinase inhibitors. Imatinib, which potently inhibits several tyrosine kinases including BCR–ABL and the platelet-derived growth factor receptor (PDGFR), was initially approved for the treatment of BCR–ABL-driven chronic myelogenous leukaemia (CML) and subsequently for other indications such as the treatment of KIT-driven gastrointestinal tumours (GISTs) (reviewed in REF.¹⁶). Its remarkable clinical impact was a catalyst in the surge of activity in the field of molecularly targeted therapy in oncology, in which kinase inhibitors have continued to be prominent in the past two decades.

Box 1 | Data collection and curation

The agents that were identified as approved for marketing by the FDA were verified in the US registry of approved drugs at Drugs@FDA: FDA-Approved Drugs. Drugs that were approved by other regulating bodies were identified from the literature and press releases. The dataset of approved drugs that target kinases is provided in Supplementary Table 1.

The US NIH database ClinicalTrials.gov is the primary resource for clinical trial registration and contains more than 360,000 research studies within the United States and 219 countries worldwide. ClinicalTrials.gov is an agent-centric resource and hence a priori knowledge of the agents to be investigated and obtain information about is required. We used previously published drug–target interaction datasets^{181,236–238} and literature reviews^{21,25,239,240} as well as cross-referencing target-centric resources such as the IUPHAR Guide to Pharmacology and the OpenTargets Platform²⁴¹ and also personal communications (D. Fabbro) to build the dataset of kinase inhibitors in clinical trials. For these already-identified investigative kinase inhibitors, the mechanism of action — that is, the targeted kinases — had already been determined.

To obtain information on new kinase inhibitors entering clinical trials, the commercial resource CenterWatch was used as it posts publicly accessible weekly updates on drugs entering clinical trials as well as developments in industry pipelines. However, the molecular targets of the new agents entering clinical trials generally have to be manually verified and this information can be collated from different resources, preferably primary sources including the literature and patent information, and also other resources such as DrugBank²⁴², ChEMBL, and industry press releases and literature. Information on the clinical trials associated with each of the identified kinase inhibitors in development was obtained through ClinicalTrials.gov. Only agents with trials registered in ClinicalTrials.gov were included in the analysis and figures, although we provide information on additional agents that were found cited in the literature as currently in trials in the Supplementary information.

An advantage of our methods is that we have tried to create a unique and extensive dataset that collates agents registered in clinical trials from different sources to obtain as exhaustive a list as possible. However, owing to the dynamic nature of agents in clinical trials, as well as the time-consuming work of manually validating the mechanism of action for agents entering clinical trials, it can be difficult to maintain current drug–target resources for analysis. Hence, although kinase research is developing with many excellently curated resources, there is still difficulty in maintaining a consistent and comprehensive list of agents in clinical trials, and our curated dataset (provided in Supplementary Table 2) is likely to contain some omissions. Therefore, we consider our dataset to be a comprehensive cross-section of kinase inhibitors that have reached clinical trials.

Recent reviews on kinase inhibitors have described important aspects of kinase drug discovery, including the targeted pathways and protein families^{3,17,18}, FDA-only approved SMKIs^{19,20}, associated disease indications^{21–23} or structural aspects^{24,25}. However, to our knowledge there is not a recently published comprehensive analysis of kinase inhibitors and kinase targets in clinical trials, which we present here (see BOX 1 for details on the origin of the dataset and analysis, and Supplementary Tables 1 and 2 for a curated dataset). We cover trends in both FDA-approved kinase inhibitors and agents in clinical trials, which could substantially expand the proportion of the kinome that is therapeutically targeted. With such opportunities in mind, we also discuss trends and strategies in kinase inhibitor design.

Trends for approved kinase inhibitors

Since the approval of fasudil in 1995, the number of approved kinase inhibitors worldwide has increased to 98 drugs, 71 of which are SMKIs that have been approved by the FDA (as of May 2021). Remarkably, the number of approved SMKIs has more than doubled in the past 5 years with 37 FDA approvals, and SMKIs constitute approximately 15% of all novel drug approvals by

the FDA from 2016 to 2021. Ten monoclonal antibodies (mAbs) that target receptor tyrosine kinases (RTKs) have also been approved by the FDA. Sixteen additional SMKIs and one mAb have been granted approval by other regulatory agencies (see details in FIG. 1 and Supplementary Table 1).

Kinase families and targets for approved drugs. The 71 FDA-approved SMKIs target 21 kinase families that constitute approximately 20% of the kinome, which corresponds with previous estimates of the coverage of protein kinase targets^{24,26–28}. Kinases targeted by a drug that has been FDA-approved (which are typically considered clinically validated by industry standards) include members of families in five of the eight major ePK groups (TK, TKL, STE, CMGC and AGC), one family in the atypical protein kinase group (PIKK) and one family in the lipid kinases (PI3K; phosphatidylinositol 4,5-bisphosphate 3-kinase). Specifically, these 71 SMKIs primarily inhibit approximately 42 proteins within these groups and most of them — 49 SMKIs — predominantly target 30 proteins that are members of 15 families in the TK group (FIG. 2). Although the TK group is the most exploited kinase group, only approximately 30% of it is targeted, indicating that there is still significant room for further exploration.

Members of the HER family (HER1–4) of RTKs are the most targeted, with eight FDA-approved SMKIs and eight FDA-approved mAbs that target these proteins. The vascular endothelial growth factor receptor (VEGFR) family of RTKs has also been extensively targeted, with seven FDA-approved SMKIs and one mAb, although all of the SMKIs are non-selective inhibitors that also interact with other RTKs. Inhibition of Janus kinases (JAKs) has been another popular therapeutic strategy, and so far five SMKIs that target this family have been approved by the FDA.

Approved kinase inhibitors in oncology. There is a large body of clinical evidence that supports the driver role of kinases in cancer owing to their aberrant activation by either translocations or activating mutations^{29–32}. Chromosomal translocations produce fusion proteins with abnormal localization that can be potentially oncogenic³³. Identification and characterization of these disease drivers has facilitated the design and approval of molecularly guided cancer therapies, beginning with the pioneering example of imatinib to treat CML driven by the *BCR-ABL* translocation, which results in a protein with elevated tyrosine kinase activity³⁴.

The majority of FDA-approved SMKIs (61; 89%) and all the FDA-approved mAbs that target kinases (ten mAbs) have oncology indications. Following on from imatinib, four further SMKIs that target ABL have been approved so far: nilotinib, dasatinib, bosutinib and ponatinib^{35,36} (see BOX 2 for details on the development of ABL inhibitors). It is noteworthy that treatment of CML with SMKIs has been shown to be long-lasting and that a substantial proportion of patients with chronic phase CML (up to 40%) did not relapse after cessation of therapy^{37,38}.

More than 20% (19 SMKIs and two mAbs) of the approved agents in our dataset have been approved for

Eukaryotic protein kinases (ePKs). There are eight main groups of eukaryotic protein kinases: AGC (protein kinase A, G and C); CaMK (calcium/calmodulin-dependent kinases); CMGC (cyclin-dependent kinases, MAP kinases, glycogen synthase kinases, CDC-like kinases); TK (tyrosine kinases); STE (homologues of sterile 7); CK1 (casein kinases); TKL (tyrosine kinase like); and the RGC (receptor guanylate cyclase) groups.

treatment of non-small-cell lung cancer (NSCLC), which is significant given that lung cancer is the leading cause of cancer death among both men and women, and 80–85% of lung cancers are NSCLC^{39,40}. Approvals for NSCLC illustrate an important trend in kinase inhibitor development in oncology in general, in which identification

of the molecular characteristics of tumours enables the development and application of first-generation SMKIs, as well as guiding further drug development to overcome the emergence of resistance⁴¹. In fact, next-generation inhibitors that address acquired resistance comprise up to 70% of the drugs that target seven major kinase




Fig. 1 | Timeline of approved kinase inhibitors. Beginning with the approval of fasudil in 1995, the timeline indicates the year a novel kinase family became validated (that is, the first year an agent targeting that kinase family was approved) and each of the small-molecule kinase inhibitors (SMKIs) that have been approved. Seventy-one SMKIs have been approved by the FDA; eight further SMKIs have been approved by the National Medical Products Administration (NMPA) in China; five by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan; one approved solely by the EMA, and two approved by the Ministry of Food and Drug Safety (MFDS) in South Korea (all non-FDA approvals are indicated by

an asterisk). Eleven monoclonal antibodies have also been approved (indicated by a red square): ten by the FDA and one by the NMPA. Many of the kinase inhibitors have also been approved by the EMA; this timeline prioritizes approval dates from the FDA first. Several of the kinase inhibitors not approved by the FDA have been approved by more than one other regulatory agency, and the first date of approval with the corresponding regulatory agency is emphasized. Drugs that have been approved for non-oncology indications are denoted with a blue square. The suffix nomenclature for kinase inhibitors and monoclonal antibodies is provided in the key. TK, tyrosine kinase.

Tyrosine kinase group




Fig. 2 | FDA-approved kinase inhibitors mapped onto the human kinome. The kinase targets of the 71 FDA-approved small-molecule kinase inhibitors (SMKIs) are mapped onto a phylogenetic representation of the human kinome. The primary kinase targets are identified, although many SMKIs cross-react with other kinases and in reality bind in varying degrees to other kinases. The type of kinase inhibitor is also indicated. Tirbanibulin targets the peptide substrate site of SRC.

gene families: *NTRK*, *ABL*, *ALK*, *BTK*, *FLT3*, *KIT* and *MET*. Next-generation sequencing has become the gold standard in sequencing tumours in NSCLC to detect driver mutations and facilitate comprehensive testing of multiple gene targets in a single assay. This has helped to characterize driver alterations in genes such as *EGFR*, *ALK*, *ROS1*, *NTRK* and *MET*, which are now targeted by FDA-approved drugs^{42,43}.

The first SMKIs to be approved for NSCLC in the early 2000s, gefitinib and erlotinib, targeted epidermal growth factor receptor (EGFR) based on its important role in tumour growth and progression⁴⁴. However, mutation-induced drug resistance commonly occurs with SMKIs that target EGFR. In particular, T790M gatekeeper mutations arise in up to 50% of patients treated with EGFR inhibitors⁴⁵. The single-point substitution mutation (L858R) in exon 21 and exon 19 deletions, which are often referred to as ‘classical’ EGFR activating mutations as they account for 85–90% of EGFR kinase domain mutations⁴⁶, are identified as sensitizing mutations associated with different clinico-pathological features^{47,48}. Exon 20 frame insertions are also activating mutations; however, they are not inherently sensitive to

EGFR inhibitors and have been associated with poor patient prognosis⁴⁹. Next-generation covalent SMKIs including afatinib and dacomitinib that are active against mutations such as T790M have been approved by the FDA, and the third-generation inhibitor osimertinib, which selectively targets activating mutations as well as the T790M resistance mutation, has also been approved⁵⁰.

Rearrangements in *ALK*, which produce an abnormal ALK protein that promotes cellular proliferation and migration, are identified in approximately 5% of cases of NSCLC, and the first ALK inhibitor, crizotinib, was approved in 2011 (REF⁵¹). *ROS1*, which is closely related to *ALK*, is also targeted by *ALK* inhibitors, and *ROS1* rearrangements have an incidence of approximately 1–2% in NSCLC⁵². Furthermore, acquired *ROS1* resistance mutations occur in up to 60% of crizotinib-refractory patients⁵³. Second- and third-generation compounds have been developed to improve on crizotinib’s therapeutic characteristics and combat resistance mutations. Four additional SMKIs that target *ALK* and/or *ROS1* translocations have since been approved by the FDA: ceritinib, alectinib, brigatinib and lorlatinib⁵⁴. Recently, four further SMKIs that target disease-related mutations

that affect specific kinases have been approved for NSCLC: selpercatinib and pralsetinib for the treatment of *RET*-fusion-positive NSCLC; and capmatinib and

tepotinib for the treatment of *MET*-mutation-positive NSCLC^{55–58}.

Targeting tumour angiogenesis is an important anti-cancer strategy, and many approved kinase inhibitors have successfully targeted the angiogenic pathways driven by VEGFR, PDGFR, KIT, fibroblast growth factor receptors (FGFRs) and *MET* for different indications. For example, there are five FDA-approved SMKIs approved for renal cell carcinoma that inhibit VEGFR as well as other RTKs, and also two approved rapalogue inhibitors, temsirolimus and everolimus, that target mTOR⁵⁹, which is downstream in the VEGFR signalling pathway⁶⁰. Metastatic colorectal cancer (CRC) has also been treated via VEGFR inhibition with the FDA-approved mAb ramucirumab and the SMKI fruquintinib, which is approved in China. Medullary thyroid carcinoma has been addressed by the VEGFR inhibitors vandetanib, cabozantinib and lenvatinib, as well as the previously mentioned RET inhibitors pralsetinib and selpercatinib.

PDGFR and KIT are inhibited by imatinib, and this activity led to its FDA approval for GISTs in 2002 (REF.⁶¹). As with other cancers, further SMKIs have been developed to improve activity and/or address resistance to first-generation drugs, with two such agents, avapritinib and ripretinib, approved in 2020 that target particular PDGFR and KIT activation loop mutants, which are responsible for relapse of up to 85–90% of patients with GISTs⁶². Inhibition of the angiogenic FGFR pathway has more recently been validated as a therapeutic strategy, with FDA approval of erdafitinib in 2019 for the treatment of FGFR-altered advanced urothelial carcinoma and FDA approval of pemigatinib in 2020, which is the first targeted treatment for cholangiocarcinoma, an aggressive tumour characterized by *FGFR* driver mutations^{63,64}.

Other RTK protein families have been targeted by approved kinase inhibitors for various cancer indications. Among the most prominent are drugs that target HER2 to treat breast cancer, which include nine of the approved kinase-targeted agents in the dataset. These include the HER2-targeted mAb trastuzumab, which was approved in 1998 and provides a pioneering example of the use of an RTK-targeted agent being guided by companion diagnostics, and the very recently approved HER2-targeted mAb margetuximab, as well as four SMKIs, lapatinib, neratinib, tucatinib and pyrotinib (approved in China) that are also used to treat patients with HER2⁺ breast cancer⁶⁵. Two antibody–drug conjugates that target HER2, trastuzumab–emtansine and trastuzumab–deruxtecan, are also included in our dataset. Although the cytotoxic payload is a key driver of the anticancer activity of these antibody–drug conjugates rather than inhibition of the activity of HER2 alone, we include them for completeness.

Various intracellular kinases have also been targeted by approved SMKIs. Targeting CDK4 and CDK6, which have important roles in cell division, has been so successful that three SMKIs, palbociclib, ribociclib and abemaciclib, are now the standard of care in particular breast cancer indications⁶⁶. The most recent CDK4/CDK6 inhibitor, trilaciclib, was approved in 2021 for small cell lung cancer myelopreservation therapy⁶⁷.

Box 2 | Developing multiple generations of ABL kinase inhibitors

Imatinib revolutionized the treatment of chronic myelogenous leukaemia (CML) and provided proof for the concept that small molecules that specifically target molecular drivers of cancer, such as the mutant BCR–ABL kinase in CML, can provide effective therapy. Various efforts have been made to develop second- and third-generation ABL inhibitors that could overcome the intrinsic clinical resistance of CML to imatinib due to mutations in the kinase domain of ABL (including the gatekeeper mutation T315I)^{109,243,244}. One approach has been structure-based drug design, enabled by the elucidation of the imatinib–ABL co-crystal structure, to improve the molecular recognition of inhibitors in the ATP-binding site, which resulted in the approval of nilotinib and ponatinib^{245–249}. A second approach in which compounds were screened against both wild-type and mutant BCR–ABL led to the approval of dasatinib and bosutinib as broad-spectrum BCR–ABL inhibitors. However, except for ponatinib, none of these second-generation ATP-binding-site-directed BCR–ABL inhibitors was able to inhibit the gatekeeper T315I mutant.

A phenotypic screen using BCR–ABL-transformed cell lines resulted in the discovery of GNF-2, which seemed not to be directed to the ATP-binding site of ABL, as it was unable to inhibit enzymatic ABL kinase activity when the kinase domain only of ABL was used²⁵⁰. The structure of ABL with its regulatory SH2 and SH3 domains lacking the last exon showed that the N terminus of ABL was myristoylated and that myristate binding into a cylindrical pocket located at the C terminus of the kinase domain (the myr pocket)^{244,245} led to an auto-inhibited conformation^{136,137}. However, when BCR is fused to the N terminus of ABL, the N-terminal myristoyl is lost, which results in the constitutive ABL kinase activity of BCR–ABL^{136,137}. The binding of GNF-2 into the myr pocket was demonstrated by X-ray crystallography and NMR¹³⁶. In addition, binding of GNF-2 to the myr pocket was disrupted by point mutations that also conferred resistance to the ability of GNF-2 to inhibit cellular BCR–ABL activity^{251,252}. Further structural and experimental analyses indicated that GNF-2 could allosterically inhibit BCR–ABL kinase activity, even with the recalcitrant T315I gatekeeper mutation in ABL²⁴⁵. This led to a search for second-generation myr-pocket binders (third-generation ABL inhibitors), resulting in the discovery of ABL001 (asciminib; also known as STAMP (specifically targeting the ABL myristoyl pocket)), which can induce an auto-inhibited conformation of even the ABL–T315I mutant^{245,251}.

The improved potency of asciminib against wild-type ABL and ABL–T315I translated into a high degree of synergistic activity with ATP-site-directed inhibitors against cells transformed with BCR–ABL–T315I¹³⁶. This inhibitor is among the most potent and specific ABL kinase inhibitors known to date. Asciminib has been tested in clinical trials involving heavily pretreated patients with CML who had resistance to or unacceptable side effects from other kinase inhibitors, including patients in whom ponatinib had failed and those with a T315I mutation. A phase III trial met its primary end point, showing that treatment with asciminib resulted in a higher rate of major molecular responses than bosutinib²⁵³, and a regulatory submission for asciminib is expected in 2021.

The development of BCR–ABL kinase inhibitors illustrates some general lessons for kinase drug discovery. First, allosteric kinase inhibitors can be very selective; asciminib is one of the most selective kinase inhibitors among the synthetic SMKIs. Second, biochemical assays to search for kinase inhibitors are best done with native and full-length proteins if possible to have access to diverse regulatory interactions. Third, understanding the mechanism of action of kinase inhibitors requires time and labour-intensive commitment to medicinal chemistry, pharmacology, biochemistry, biophysics, and cell and structural biology. It took 13 years from the approval of imatinib to the phase I studies with asciminib. Finally, it is important to understand the disease that is being treated by kinase inhibitor drugs. Imatinib and the other inhibitors that target ABL for the treatment of CML still stand out in terms of their unprecedented efficacy compared with many kinase inhibitors developed for other cancers in the past two decades. This may reflect that imatinib and the other BCR–ABL inhibitors are conceptually closer to preventing cancer, namely the acute phase of CML (blast crisis) rather than treating a cancer, which may often be at an advanced stage. Indeed, the chronic phase of CML, in particular the early phase, could be viewed as a myeloproliferative disorder rather than a cancer. Many myeloproliferative disorders are driven by tyrosine kinases, for example, polycythemia vera (JAK2), chronic myelomonocytic leukaemia (PDGFR) and hypereosinophilic syndrome (PDGFR), although they rarely turn into cancer, unlike CML.

Metastatic melanoma is a challenging disease to treat, and the commonly observed *BRAF*^{V600E} mutation makes this cancer particularly aggressive. Six SMKIs have been approved for this indication: three agents are BRAF inhibitors (vemurafenib, dabrafenib and encorafenib) and three are MEK inhibitors (trametinib, cobimetinib and binimetinib)⁶⁸. Furthermore, the MEK and BRAF combination regimen of dabrafenib plus trametinib was also approved by the FDA in 2018 (REF.⁶⁹). Additionally, evidence indicates that combinations of targeted therapy with SMKIs, and particularly MEK and BRAF inhibitors, plus immunotherapy can achieve durable responses with better therapeutic effectiveness^{70,71}.

The PI3K–AKT–mTOR pathway is involved in cell survival, metabolism and regulation of cell growth. The dysregulation of this pathway in many cancers²³ has led to extensive efforts to target its components. Such efforts have led to the only approved kinase inhibitors that target lipid kinases, beginning with FDA approval of idelalisib, a first-in-class SMKI that targets PI3K δ , for the treatment of various lymphomas in 2014 (REFS^{72,73}). Since then, the dual PI3K α/β inhibitor copanlisib was approved in 2017 for follicular lymphoma⁷⁴, the dual PI3K δ/γ inhibitor duvelisib was approved in 2018 for several lymphomas⁷⁵ and the PI3K α -selective inhibitor alpelisib was approved in 2019 for the treatment of breast cancer⁷⁶. Three SMKIs have been approved that target mTOR (see above), including sirolimus — one of the earliest kinase inhibitors — which has been approved for a variety of indications, both oncological and non-oncological.

Substantial progress has been achieved by targeting kinases for the treatment of other haematological malignancies. Notably, mantle cell lymphoma and chronic lymphocytic leukaemia are being addressed by three FDA-approved Bruton tyrosine kinase (BTK) inhibitors^{25,77}: ibrutinib, acalabrutinib and zanubrutinib. Significantly, all three drugs act covalently, and the success of ibrutinib had an important role in catalysing a re-evaluation of covalent inhibition as a drug design strategy (see below), together with afatinib (see above).

Finally, kinase inhibitors are also at the forefront of pioneering efforts to develop anticancer drugs based on the molecular characteristics of the tumour, instead of the tissue of origin⁷⁸. Three decades after the discovery of NTRK1 as a component of an oncogenic fusion gene product in CRC⁷⁹ and the subsequent discovery of *NTRK2* and *NTRK3*, the pioneering pan-TRK inhibitor larotrectinib became only the second tumour-agnostic therapy to enter the market (after pembrolizumab) following its FDA approval in 2018 for the treatment of patients with solid tumours that have an *NTRK* gene fusion⁸⁰. Since then, it has been joined by the multikinase inhibitor entrectinib, which is also approved for patients with solid tumours that have an *NTRK* gene fusion⁸¹. Other kinase inhibitors are also being investigated in tumour-agnostic development programmes, including the approved RET inhibitors pralsetinib and selpercatinib⁷⁸.

Approved kinase inhibitors beyond oncology. Many kinases are involved in the regulation of immune responses. For instance, JAKs are the key components

for T helper cell (T_H1, T_H2 and T_H17) immune responses as they are secondary messengers for many cytokines, including interferons and interleukins^{82,83}. Eleven SMKIs — more than 13% of the approved SMKIs — have been approved for immune system-related indications, mostly autoimmune and inflammatory disorders.

The first kinase inhibitor to be approved outside oncology was ruxolitinib, an inhibitor of JAK1 and JAK2 that was approved by the FDA for the treatment of patients with intermediate or high-risk myelofibrosis in 2011, following the recognition that activating mutations in *JAK2* caused a group of myeloproliferative neoplasms⁸⁴. A JAK2 inhibitor, fedratinib, was also approved for such diseases in 2019.

Rheumatoid arthritis is the autoimmune disease with the most approved SMKIs (five overall, and three approved by the FDA). All five SMKIs selectively target isoforms of JAK, and include the first SMKI to be approved for rheumatoid arthritis — tofacitinib in 2012 — followed by baricitinib, upadacitinib, peficitinib and filgotinib. Peficitinib predominantly inhibits JAK3 and was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan in 2019. Filgotinib is a selective JAK1 inhibitor that has received approval by the EMA and PMDA; however, the FDA has postponed a decision on the new drug application for it for safety reasons (see Related links). JAK kinase inhibitors are also being investigated for other immune disorders, and delgocitinib, a pan-JAK inhibitor that was approved in 2020 by the PMDA, is the first kinase inhibitor approved for the skin disorder atopic dermatitis.

The kinase SYK, which is involved in innate and adaptive immune responses, is implicated in the development of allergic and autoimmune diseases, as well as in haematological malignancies^{85–87}. Fostamitinib, a first-in-class SYK inhibitor, was approved by the FDA in 2018 for chronic immune thrombocytopenia owing to its ability to reduce antibody-mediated destruction of platelets⁸⁸. Rejection prophylaxis for organ transplantation and graft-versus-host disease are also immune-related issues that are amenable to kinase inhibition. Two agents have been approved for each of these disorders: ibrutinib and ruxolitinib.

Finally, several SMKIs have been approved for diseases beyond oncology and immunology. These include the ROCK1 and ROCK2 inhibitor fasudil for cerebral vasospasm (mentioned above), the mTOR inhibitor everolimus for tuberous sclerosis complex-associated partial-onset seizures⁸⁹, the VEGFR inhibitor nintedanib for idiopathic pulmonary fibrosis⁹⁰, the FLT3 inhibitor midostaurin for advanced systemic mastocytosis⁹¹ and another ROCK1/ROCK2 inhibitor, netarsudil, for glaucoma and ocular hypertension⁹².

Classes of agents. Nearly all of the FDA-approved SMKIs are directed towards the kinase ATP-binding site (63 SMKIs), with the exception of three rapalogues, four MEK inhibitors and the dual SRC and tubulin polymerization inhibitor tirbanibulin, which targets the peptide substrate site⁹³ (see below for further discussion of binding modes). The conservation of the ATP-binding site in the human kinome means that ‘ATP mimetics’ often

cross-react with many other different kinases, resulting in compounds with promiscuous profiles. Promiscuous compounds such as dasatinib⁹⁴ or sunitinib^{95,96} have been termed multitarget inhibitors and can have some toxicological liabilities⁹⁷. However, this cross-reactivity can also be potentially advantageous. For instance, the activity of imatinib against multiple kinases has enabled its application in multiple indications, such as CML driven by the *BCR-ABL* translocation, GISTs driven by KIT and hypereosinophilic syndrome driven by PDGFR α deregulation. Inhibiting multiple nodes in cellular networks by blocking two or more kinases can also have synergistic effects that might be clinically useful; for example, targeting the BRAF and MEK pathways with the previously mentioned combination of dabrafenib plus trametinib⁹⁸.

The cell surface location of RTKs has been successfully exploited by ten FDA-approved mAbs for the treatment of breast cancer, CRC, NSCLC, soft tissue sarcoma and hepatocellular cancer. The mechanism of action of such agents is more complex than inhibition of kinase activity by SMKIs, and could include blockade of ligand binding (thereby preventing kinase activation), promoting receptor internalization and antibody-dependent cellular cytotoxicity⁹⁹.

Trends in kinase inhibitor design

The identification of SMKIs has been advanced substantially by understanding of the structures of their binding sites. More than 5,500 catalytic domain structures have been published so far, covering approximately 300 kinases from 104 families. In this section, we overview the key features relevant to structure-based drug design and trends in the development of SMKIs of different types.

Structural features of the kinase catalytic domain. The architecture of the kinase fold was first described in 1991 by Knighton et al.^{100,101}, who reported the structure of protein kinase A (PKA) in complex with ATP-Mg²⁺ and an inhibitory peptide. This structure revealed a bilobal arrangement including an N-terminal smaller lobe containing a five-stranded antiparallel β -sheet (β 1– β 5), the conserved regulatory α C helix, two additional helical segments, as well as a larger C-terminal lobe of mostly α -helices (FIG. 3a).

The ATP cofactor was found sandwiched between the two lobes and forming hydrogen bonds between the adenine ring and the hinge region, which established a backbone connecting the lobes. These hydrogen bonds represent important anchor points for the design of ATP mimetic inhibitors and define the basic kinase inhibitor scaffolds. ATP is also coordinated by the glycine-rich loop (G-loop, also called phosphate-binding loop (P-loop)). This is a highly flexible region that is present in the β -sheet structures β 1 and β 2 with the consensus sequence motif GXGX ϕ G, where ϕ represents a hydrophobic residue. A second key sequence motif, (V)AxK, is located in β 3.


A structural hallmark of active kinases is a conserved salt bridge formed between the lysine residue in the (V)AxK motif and a conserved glutamate located in α C positioning α C (' α C-in' conformation). The α C helix has

an important regulatory role, as the (V)AxK salt bridge contributes to the coordination of the phosphate groups of ATP. In inactive kinases, the α C helix dislodges from its position in the active state moving outwards (α C-out) and it often also rotates the central conserved glutamate away from the ATP-binding site.

The C terminus of the α C helix in the α C-in state is additionally stabilized by interaction with the conserved tripeptide Asp-Phe-Gly motif DFG, which also anchors the N terminus of the activation segment. In its active 'DFG-in' conformation, the DFG aspartate residue points towards the phosphate moieties of ATP, coordinating a catalytically important Mg²⁺ ion. In inactive kinases, the DFG is mobile, dislodging the phenylalanine residue. This so-called 'DFG-out' conformation opens a deep, mainly hydrophobic binding pocket¹⁰² (see below). The DFG-out movement also results in unstructuring of the activation segment, a mobile structural element of variable length and sequence that harbours the DFG motif, the activation loop (A-loop) and ends with the helical APE (Ala-Pro-Glu) motif. The A-loop also contains phosphorylation sites that regulate kinase activation of kinases that are not constitutively active, by either autophosphorylation or transphosphorylation¹⁰³. Finally, the catalytic loop harbours a highly conserved Y/HRD (Tyr/His-Arg-Asp) motif with the strictly conserved aspartate, which is required for catalysis.

The 3D structure of ePKs is highly conserved, including a network of structurally important hydrophobic residues¹⁰⁴. These residues form two spines that in the active state connect and properly align both kinase lobes and position key sequence motifs for catalysis^{104,105}. One spine is called the catalytic spine (C-spine), which is complemented by the adenine ring system of the cofactor ATP, and connects structural elements at the hinge side of the kinase domain. A second hydrophobic spine called the regulatory spine (R-spine) senses the proper alignment of the β 4 sheet, α C, the DFG motif and the lower lobe α E helix when in the active state (FIG. 3b). In inactive states, the displacement of R-spine residues causes the R-spine to be broken. The functional importance of spine residues has been validated experimentally by mutagenesis studies that demonstrated that hydrophobic contact by spine residues is required for proper catalytic function¹⁰⁶. Owing to their proximity to the ATP-binding site, many kinase inhibitors interact with spine residues or even intercalate or alter spine interactions.

A residue called the gatekeeper bridges the C-spine and the R-spine (M120 in PKA) and is located at the N terminus of the hinge region. The importance of the gatekeeper residue for drug development was recognized early¹⁰⁷. The presence of a small gatekeeper residue such as threonine, although not common, can enable the design of inhibitors that are selective over other kinases because it makes the back pocket accessible to small molecules; this means that inhibitors that bind to this pocket are prevented from binding to other kinases that have large hydrophobic residues in the gatekeeper position¹⁰⁸. Glycine residues are not present in the gatekeeper position in human kinases, which led to the design of bulky ATP analogues that specifically target kinase gatekeeper



mutants. However, gatekeeper mutations that shift to bulkier residues that sterically exclude inhibitors are a common cause of kinase drug resistance¹⁰⁹.

Comprehensive selectivity testing. The development of large panels of kinase assays for screening has enabled comprehensive assessment of inhibitor selectivity in and outside cells¹¹⁰. The assays are either enzyme kinetic assays, stability-based assays¹¹¹ or displacement assays using recombinant proteins¹¹² or cellular extracts in combination with mass spectrometry^{113,114}.

Recently, assay systems have also been established that allow studies on inhibitor binding to full-length kinases and selectivity in live cells^{115,116}. In particular, besides the well-established potency criteria, kinetic aspects of ligand binding have also emerged as important parameters for ligand optimization^{117,118}.

Strategies for rational inhibitor design. The highly dynamic nature of protein kinases allows for the design of inhibitors that recognize the active or diverse inactive conformations. The inactive state of kinases is

◀ **Fig. 3 | Structural features of the kinase catalytic domain and inhibitor binding modes.** **a** | Structural overview of the kinase catalytic domain, based on the structure of protein kinase A (PKA) in ribbon representation²³⁵. The main secondary structure elements are labelled in parts **a** and **b**. The ATP cofactor is shown in ball and stick representation. Mobile structural elements that regulate kinase activity including the glycine-rich loop (G-loop; blue), the activation segment (turquoise) and α C helix (red) are highlighted. Two Mg^{2+} ions are shown as solid spheres. **b** | Aligned catalytic (blue) and regulatory (yellow) spine residues in the PKA active state. The gatekeeper residue (M120, grey) bridges the two spines. The adenine ring of ATP bridges N-terminal and C-terminal lobe catalytic spine residues. The secondary structure elements are coloured in light green for sheets and red for helices in parts **c–f**. **c** | Details of the type 1 binding mode in ABL kinase. The binding site boundaries are shown as a transparent surface. Key residues are shown in ball and stick representation. Hydrogen bonds are shown as dotted lines. **d** | Details of the type 2 binding mode in ABL kinase. Labelling of residues and structural elements is identical to panel **c**. The large pocket created by the Asp-Phe-Gly motif (DFG)-out movement that is characteristic of this binding mode is highlighted by a dashed circle. **e** | Details of the type 1.5 binding mode in BRAF kinase complexed with dabrafenib. Binding of the inhibitor breaks the regulatory spine by inducing an α C-out movement. The salt bridge between α C E501 and K483 is not present in this inactive conformation. **f** | Example of a type 3 inhibitor binding mode in the kinase MEK1. The inhibitor occupies a pocket (dashed circle) created by an α C-out movement and an inactive helical conformation of the activation segment. The cofactor ATP- Mg^{2+} shown in ball and stick representation binds to the ATP-binding site and the DFG motif is in a DFG-in conformation. APE, Ala-Pro-Glu motif.

particularly structurally diverse and has been extensively explored in drug development. More than 80 possible ligand-binding sites that are present in the kinase catalytic domain have been catalogued and described^{3,119}. A detailed description of this area is beyond the scope of this Review and we restrict our description to the main binding modes that are now well-established in kinase drug discovery (for detailed reviews, see REFS^{25,120}).

Type 1 inhibitors target the kinase active state (FIG. 3c). The central purine moiety of the inhibitor mimics hinge-binding hydrogen bonds of ATP, and both α C and the DFG motif are in their active 'in' position. However, in this structure, the G-loop is not in an active conformation forming an aromatic stacking interaction with the purine ring and Y253. Aromatic amino acids are frequently found at the tip of the G-loop. In the ATP-bound active state, these residues are oriented away from the ATP site. Interestingly, so-called 'folded P-loop conformations' have been observed in many kinase inhibitor complexes, and this conformation has been associated with favourable inhibitor selectivity¹²¹.

Type 2 inhibitors bind to an inactive kinase state, which is characterized by the DFG-out conformation (FIG. 3d). As shown in the figure, the outward movement of the DFG motif creates a large hydrophobic pocket that is targeted by the trifluoromethylphenyl moiety of this inhibitor. The α C helix maintains its active state α C-in position, as indicated by the formation of the canonical salt bridge between (V)AxK K271 and the conserved α C glutamate E286, while the G-loop maintains its folded conformation.

Many intermediate binding modes between those of canonical type 1 and type 2 inhibitors exist, and some authors have introduced type 1.5 binding modes. The definition of type 1.5 inhibitors in the kinase literature is not clear, however. A stringent definition could be an inhibitor that disrupts the R-spine, but the term has also been used to describe inhibitors for which binding results in any type of structural deviation from the

ideal active conformation, including abnormal G-loop conformations and auto-inhibitory conformations of the activation segment¹²². As many of these structural elements are highly mobile, and their conformations may depend on crystal packing, we consider it more useful to limit this binding mode type to inhibitors that disrupt the R-spine without targeting the canonical type 2-specific DFG-out pocket (FIG. 3e). In the BRAF-dabrafenib complex, the α C helix is moved outwards, resulting in a broken R-spine and a broken (V)AxK (K483) α C glutamate (E591) salt bridge, while the DFG motif remains in a DFG-in position¹²³.

Non-canonical binding modes represent attractive design strategies, as these compounds are often highly selective compared with canonical type 1 and type 2 inhibitors and have prolonged target residence times. For instance, the EGFR inhibitor lapatinib binds to a DFG-in conformation, but it induces large structural rearrangements that explain its high selectivity for EGFR¹²⁴. Similarly, the protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) inhibitor GSK2606414 and the MET inhibitor SGX523 target an inactive conformation of the activation segment. The ERK1/ERK2 inhibitor SCH772984 specifically interacts with a unique binding pocket created by an α C-out and a folded P-loop conformation^{125–128}. The Kinase-Ligand Interaction Fingerprints and Structures (KLIFS) database provides a valuable resource for studies on ligand interactions and the distribution of diverse binding modes across the kinome¹²⁹.

Recent studies have also examined the role of water in ligand design. Early models considered the displacement of water based only on the simplistic view of entropic gain when ligands displace binding-site waters. More refined computational tools now characterize each water molecule seen in structural models in detail to evaluate the role of water in ligand potency, conformational change and ligand off-rates^{130,131}.

Trends in the chemistry of approved kinase inhibitors. The ATP-binding site is the main site targeted by approved SMKIs, accounting for 63 of the 71 FDA-approved drugs. Similar to the ATP adenine ring, ATP mimetic inhibitors are anchored to the kinase hinge backbone by hydrogen bonds. Several scaffolds have been developed that act as hinge binders (FIG. 4). Fused six-membered ring systems, such as (iso)quinoline and quinazoline, which was first established in the development of fasudil and subsequently gefitinib and erlotinib, have been the most frequently used ATP mimetics, with 18 approved SMKIs. The aminopyrimidine and closely related aminopyridine moiety, which was used in imatinib, have also remained frequently used hinge binders, with 17 approved SMKIs.

The third group of hinge binder moieties are fused five- and six-membered ring systems such as pyrrolopyrimidines and pyrrolopyridines, purines, oxoindoles and pyrrolo or imidazo triazines. Structurally, pyrazolo aminopyrimidines and imidazo aminopyrazines are also related to this class of hinge binders, but based on their hinge-binding modes, they should be considered as derivatives of aminopyrimidines. Non-aromatic




Fig. 4 | **Chemical scaffolds used in approved kinase inhibitors.** Chemical structures of the major hinge-binding scaffolds used in approved kinase inhibitors. Shown is the distribution of hinge-binding scaffolds for all ATP mimetic inhibitors (centre) as well as the structures of the most frequently used moieties. The number of approved drugs using each major scaffold is provided in brackets and each chemotype has been linked to the central pie chart by colour and numbering. Hydrogen bond donors and acceptors are indicated by red arrows.

hinge-binding motifs are represented by carboxamides. A total of 17 SMKIs harbour diverse hinge-binding scaffolds, but the narrow chemical space explored in the development of two-thirds of the approved SMKIs is astounding.

Allosteric inhibitors. Most signalling kinases are expressed in an inactive state that is activated by many different mechanisms, such as structural changes induced by post-translational modification or through interaction with scaffolding proteins or flanking regulatory domains. Thus, the key role of kinases regulating cellular signalling requires a high degree of catalytic domain plasticity. This characteristic has been widely explored through the development of allosteric inhibitors that prevent kinase activation.

Allosteric kinase inhibitors differ in the activation mechanisms that they prevent and they have therefore been classified only by their location of binding. Type 3 inhibitors bind adjacent to the ATP-binding site in a pocket induced by an α C-out conformation and in some cases by an inactive conformation of the A-loop (FIG. 3f). All four clinically approved MEK1/MEK2 inhibitors are examples of type 3 inhibitors that bind to the allosteric back pocket. The DFG is in an active 'in' conformation, allowing simultaneous binding of the type 3 inhibitor

and ATP. Some type 3 inhibitors also form polar interactions with the phosphate backbone of ATP, resulting in an ATP-uncompetitive mode of action. However, an increasing number of type 3 inhibitors bind to the canonical back pocket but stabilize a DFG-out conformation. Examples include allosteric inhibitors that target FAK¹³², TRKA¹³³, PAK1 (REF.¹³⁴) and IGF1R¹³⁵. Remarkably, these inhibitors show isoform selectivity against closely related family members.

Type 4 inhibitors bind to allosteric sites that are distantly located from the ATP-binding site (schematic representations of binding types in FIG. 5). An example of a type 4 inhibitor is the ABL inhibitor GNF-2, which binds to an induced pocket in the C-terminal kinase lobe that also serves as a binding site for lipids such as myristate¹³⁶ (BOX 2). This type 4 inhibitor makes use of the unique ABL activation mechanism: in inactive ABL kinases, a myristoylated residue at the N terminus of ABL binds to the C-lobe binding pocket, which results in the stabilization of a closed inactive conformation¹³⁷. In the oncogenic fusion protein BCR-ABL, this mechanism of inactivation is lost owing to the presence of the N-terminal fusion partner BCR, which results in constitutively active ABL. GNF-2 and the investigational type 4 inhibitor asciminib (ABL001) mimic the binding of myristate and induce an inactive state similar to that

observed for the inactive wild-type protein. Interestingly, combining myristate mimetic ABL type 4 inhibitors with conventional ATP-competitive drugs could reduce the risk of development of drug-resistant mutations¹³⁸.

Several other type 4 inhibitors have entered clinical testing, including the allosteric AKT1 inhibitor MK-2206 (REFS^{139,140}), which binds at the interface between the AKT catalytic domain and the pleckstrin homology (PH) domain. The kinase is locked in an inactive conformation when it is targeted and bound by MK-2206. This also prevents recruitment of AKT1 to the plasma membrane, which is a re-localization event that is required for AKT1 activation. A wide range of preclinical allosteric inhibitors that target diverse binding sites such as the PDK1-interacting fragment (PIF) pocket¹⁴¹ have now been reported¹²⁰. Allosteric inhibitors also allow selective targeting of mutations, as demonstrated by EAI045, which targets the EGFR resistance mutants EGFR-L858R/T790M and EGFR-L858R/T790M/C797S while largely sparing wild-type EGFR¹⁴².

Allosteric targeting of protein kinases offers the opportunity to mimic natural regulatory mechanisms in a highly specific manner. The therapeutic potential of these modulators of kinase activity is enormous and the kinase field has only started to explore this targeting strategy in a clinical setting.

Covalent inhibitors. Several covalent kinase inhibitors have been approved since the pioneering approvals of the covalent EGFR inhibitor afatinib¹⁴³ and the BTK inhibitor ibrutinib by the FDA in 2013 (see above). Seven additional SMKIs have been recently approved that target either EGFR mutants or BTK (Supplementary Table 1). All currently approved covalent kinase inhibitors except acalabrutinib use an acrylamide group as the electrophile for covalent bond formation (FIG. 5b). Substitution of the alpha position in an acrylamide by an electron-withdrawing group such as a cyano group allows for the design of reversible covalent inhibitors¹⁴⁴. This has been explored in the development of several highly selective tool molecules with prolonged target residence times^{145,146}. The potential for using covalent targeting for the design of highly selective kinase inhibitors is huge and this design strategy has still not been widely explored^{147,148}.

Macrocycles. Macrocyclization has emerged as a recent strategy to improve inhibitor potency and selectivity as well as pharmacokinetic properties. Lorlatinib, for instance, has been developed on the basis of its non-cyclized template, crizotinib¹⁴⁹. Macrocyclization locked the bioactive conformation of crizotinib, which resulted in markedly improved potency against ALK and ROS, as well as outstanding central nervous system penetration¹⁵⁰. In addition, lorlatinib is effective against resistance mutations for first- and second-generation ALK inhibitors¹⁵¹, and it has improved pharmacological properties compared with its parent compound. Another interesting example of successful macrocyclization is the EGFR inhibitor BI-4020, which has been designed to target tertiary EGFR resistance mutations,

such as EGFR-L858R, EGFR-T790M and EGFR-C797S that emerge in NSCLC¹⁵².

Bifunctional inhibitors. A plethora of additional classes of inhibitor have emerged recently that comprise bisubstrate and bivalent inhibitors, as well as molecular glues that induce new protein interactions by binding to protein interfaces (FIG. 5b). These agents link inhibitors that interact with different binding sites; for example, ATP mimetic inhibitors with SH2 domain ligands or substrate-competitive inhibitors^{153–156}. Such inhibitors have been referred to as type 5 inhibitors in some publications. However, since these inhibitors are composite inhibitors that combine type 1 inhibitors via a chemical linker with a compound that targets a remote secondary binding site, we see no conceptual advantage to introducing a new name for this diverse inhibitor class. Their large molecular weight makes it challenging to develop these inhibitors clinically, but the increase in selectivity usually observed for these bidentate inhibitors may provide interesting chemical tools for target validation and functional studies.

Chemical degraders such as proteolysis-targeting chimeras (PROTACs) also fall into the class of bidentate inhibitors. PROTACs have received a lot of attention recently owing to their ability to catalytically degrade a target molecule, often with increased isoform and mutant selectivity^{157,158}. This can be achieved by linking a conventional kinase inhibitor to a ligand that binds to an E3 ligase. Protein kinases seem to be highly amenable to degradation. A recent study reported PROTAC lead compounds for approximately 200 ePKs using promiscuous kinase inhibitors¹⁵⁹. Selective PROTACs have already been developed for major kinase drug targets, including BRAF¹⁶⁰, EGFR-L858R/T790M oncogenic mutants¹⁶¹, JAK¹⁶², BTK¹⁶³, ALK¹⁶⁴, AKT¹⁶⁵, CDK6 (REFS^{166,167}), CDK9 (REF¹⁶⁸), TBK1 (REF¹⁶⁹), Aurora kinase A¹⁷⁰, TRKA¹⁷¹, FAK¹⁷² and others. As for bidentate inhibitors in general, the pharmacological challenges to develop these molecules for clinical applications are greater than for conventional small molecules, but the first compounds have now entered clinical testing¹⁷³. In the near future it is likely that more PROTACs will enter clinical development and it will be exciting to see how PROTACs perform in clinical studies compared with conventional inhibitors.

An attractive variant of PROTACs are molecular glues that bind to the interface of two proteins, resulting in the formation of a complex. In the kinase field, molecular glues that modulate kinase function were discovered early on. The macrolide rapamycin and its related rapalogues allosterically inhibit mTOR by inducing the formation of a ternary complex between FKBP12 (FK506 (tacrolimus)-binding protein 12), rapamycin and mTOR¹⁷⁴. Molecular glues can be used in the context of the ubiquitin system as selective degraders by recruiting novel substrates (neosubstrates) to E3 ubiquitin ligases. Since the identification of the E3 ligase cereblon as a target of thalidomide¹⁷⁵, several transcription factors have been identified as neosubstrates including the C2H2 zinc finger protein SALL4, a key factor in the teratogenicity of thalidomide¹⁷⁶. This explains the teratogenic mechanism of thalidomide as well as its immunomodulatory

Molecular glues


In the context of targeted protein degradation, molecular glues are small molecules that induce association of ubiquitin ligases with their target via monovalent interactions. However, designing a small molecule that can bind to both a ubiquitin ligase and a kinase in this way is highly challenging, and so molecular glues are most often identified by screening compound libraries.

Proteolysis-targeting chimeras


(PROTACs). Bivalent macromolecules composed of a flexible linker that is capped with protein-binding moieties designed to bring ubiquitin ligases and a target such as the kinase of interest into close proximity to promote its degradation. Although this strategy could enable more specific targeting of a given kinase, the large molecular size of PROTACs may pose challenges related to drug characteristics such as oral bioavailability.

a Kinase inhibition modes


Type 1 inhibitors (ATP mimic)




Type 2 inhibitors (ATP mimic)



Type 3 inhibitors (allosteric close to ATP)




Type 4 inhibitors (allosteric remote from ATP)




b Additional approaches for kinase targeting


Bivalent inhibitors




Covalent inhibitors




① Acrylamide: irreversible conjugate addition



② α-Cyano acrylamide: reversible conjugate addition



Degraders and molecular glues



◀ **Fig. 5 | Schematic representation of kinase inhibitor binding modes. a** | Kinase inhibition modes. There are four primary types of kinase inhibitor. The colour of kinases indicates their state (active: orange; inactive: grey). Type 1 inhibitors inhibit kinases at the ATP site with the Asp-Phe-Gly motif (DFG)-in and α C-in conformation (active state). Type 2 inhibitors inhibit kinases at the ATP site with the DFG-out and α C-in conformation (inactive state). Type 3 inhibitors inhibit kinases at the allosteric site that is located close to the ATP site, and the α C helix usually transits to the 'out' conformation. Type 4 inhibitors inhibit kinases at an allosteric site that is located remote from the ATP site. Type 4 inhibitors also include antibodies and their derivatives that target extracellular domains of receptor tyrosine kinases (RTKs). Type 1.5 inhibitors have been proposed (not shown), and sometimes type 1.5 and type 2 inhibitors are subdivided into types A and B depending on whether the inhibition involves the back pocket, but this classification does not take into account other kinase states. **b** | Additional approaches for kinase targeting. Bivalent inhibitors target kinases simultaneously at two different binding sites (or domains). Covalent inhibitors inhibit kinases by forming a covalent bond with nucleophilic amino acid residues. There are two types of covalent bond formation: irreversible and reversible. Degraders and molecular glues target kinases via recruitment of the ubiquitin (Ub) degradative pathway. E3, E3 ubiquitin ligase; E2, E2 ubiquitin ligase.

function by a degradation mechanism¹⁷⁷. The kinase CK1 α was also identified as a neosubstrate, which contributes to the clinical efficacy of the thalidomide derivative lenalidomide for the treatment of multiple myeloma and 5q-deletion-associated myelodysplastic syndrome^{178,179}. Selective degradation can also be induced by conventional kinase inhibitors harbouring surface-exposed moieties. Recently, the CDK inhibitor CR8-a has been shown to recruit the cullin 4 adaptor protein DDB1 (DNA damage-binding protein 1) to the CDK12–cyclin K complex, where it acts as a molecular glue and selective degrader for this kinase¹⁸⁰. Owing to their low molecular weight, molecular glues can be attractive lead compounds for drug development with very specific modes of action. However, most molecular glues have been discovered serendipitously or have been developed based on natural products, and a rational strategy for their identification is currently lacking.

Trends for investigational agents

Our analysis of ClinicalTrials.gov identified nearly 600 kinase-targeting agents registered in clinical trials, which include 475 novel SMKIs (including agents approved by other regulatory agencies and potentially seeking approval by the FDA, but not including the 71 already FDA-approved SMKIs) and also 124 biological agents (see BOX 1 for the dataset details and Supplementary Table 2 for the dataset). In comparison with previous analogous analyses, the number of SMKIs that have reached clinical development has increased more than 200% during the past 5 years, with 177 SMKIs having reached this stage in 2014 (REF.¹⁸¹) and 149 in 2010 (REF.²⁷).



Of the 475 SMKIs registered in clinical trials, nearly half of these agents — 253 — are currently in development, either in active trials or in the process of beginning new ones, while 222 were determined to not be in active development. Approximately 40% (194) of the kinase inhibitors in clinical trials target 45 novel kinase families that encompass 215 proteins (40% of the kinome), although we identify around 110 of these as the primary targets of kinase inhibitors, so a more accurate estimate is that 20% of the kinome beyond the targets validated by approved drugs is being investigated with agents in

clinical development (FIG. 6). This indicates a robust exploration of the novel kinase landscape in comparison with other major target families; for example, the proportion of novel G protein-coupled receptors being investigated with agents in clinical trials was 16% in an analogous recent analysis¹⁸².

Success rates of kinase inhibitors in clinical trials.

Using data from 475 investigative agents in more than 3,700 clinical trials and extrapolating trial completion information for the 71 already approved drugs, we estimate that the phase transition probabilities for kinase inhibitors are 72% from phase I to phase II, 66% from phase II to phase III and 86% from phase III to approval and marketing. Phase transition probabilities were calculated using descriptions from Hay et al.¹⁸³ that are based on DiMasi and Grabowski¹⁸⁴ studies. Analyses of phase transition success rates are heterogeneous in methods and data, and a direct comparison can be difficult; however, landmark studies that have investigated the success of lead indications for drugs in general have cited rates comparable to ours, such as 67–71% for phase I to II, 40–45% for phase II to III and 64–68% for phase III to New Drug Application (NDA)/Biologic License Application (BLA)^{183,185}. Our estimates are much higher than the FDA estimate of clinical research phase success rates for drugs in general, which are approximately 70% for phase I to II, approximately 33% for phase II to III and up to 30% for phase III to the next phase¹⁸⁶. Interestingly, our results are comparable to estimates made by Walker and Newell¹⁸⁷ more than a decade ago for kinase inhibitors, which calculated 80%, 69% and 85%, respectively, and indicate that kinase inhibitors have continued to have reduced overall attrition rates and continued success in the high-risk transition from phase II to phase III.

The decrease in phase transition probabilities for investigative agents during phase II studies is ubiquitous for both small-molecule and large-molecule therapies across indications, and has been analysed previously^{188,189}. Key findings from Morgan et al.¹⁸⁸ indicated lack of clinical efficacy as the principal cause, which can be mitigated by addressing three pharmacological pillars of candidate survival: exposure at the target site, target binding and expression of pharmacological activity. Both the previous analysis of kinase inhibitors¹⁸⁷ and our study indicate less agent attrition in later-stage development than the FDA estimates for drugs in general. This could be due to the repeated targeting of well-understood kinase signalling pathways and the development of more selective inhibitors that effectively inhibit kinase signalling in disease. We also note a similar overall success rate of kinase inhibitors from phase I to approval, which we estimate to be currently around 41%. This is marginally lower than the previous assessment of kinase inhibitors, which estimated an overall success rate of around 47%¹⁸⁷. However, our study comprises an additional decade of data and about three times as many drugs (546 compared with 137). Additionally, differences in methods of determining agents that are no longer active may affect the analysis (see Supplementary Table 3 for details).



◀ Fig. 6 | **Exploring the kinome. a** | Timeline of the year for which agents with novel kinase family targets entered clinical trials. The date is based on the start date of the trial of the earliest investigative agent that targets that kinase family that we could identify. Established targets are not included. For brevity, we present the first instance we identify that an investigative agent has targeted a member of a specific kinase family, although there are several examples where we describe subgroups of these families (for example, the MAPK subgroups JNK and ERK). Kinase targets that are in clinical trials for non-oncology indications are denoted with a blue square. The data include kinase targets of both biologic therapies (denoted with (B)) and small-molecule kinase inhibitors. Kinase targets for which agents are not in active trials and for which no further development has been reported (and are thus presumed discontinued) are marked with a (D). **b** | The kinase targets of the small-molecule kinase inhibitors are mapped onto a phylogenetic tree of the human kinome. Phase status is indicated by the colour of the circle, and the number of agents in clinical trials that target a given kinase is indicated by the size of the circle. CMGC, CDK, MAPK, GSK3 and CLK families; TK, tyrosine kinase.

Kinase families and targets for investigational drugs.

Established kinase families and targets continue to be actively investigated in clinical trials with novel agents. Approximately 12% (73 of 599) of the agents in clinical trials target kinases in the HER family to treat various cancers, including 26 novel SMKIs and 47 novel biologics. VEGFRs also continue to be investigated as anticancer targets, with 30 novel SMKIs and nine novel biologics targeting these RTKs in clinical trials. Furthermore, there are 54 PI3K or PI3K–mTOR pathway inhibitors in clinical trials, with six in phase III trials for a range of indications such as lymphomas (buparlisib), activated PI3-kinase delta syndrome (leniolisib) and myelofibrosis (parsaclisib). PI3K and mTOR inhibitors could also have potential for the treatment of rare genetic disorders known as overgrowth syndromes, such as PTEN hamartomas, tuberous sclerosis complex and PIK3CA-related overgrowth spectrum^{190–192}.

Outside oncology, there are currently 12 SMKIs targeting JAKs in clinical trials for various immunoinflammatory diseases, with seven of them in phase III trials. Of particular interest are the phase III-stage JAK3 inhibitor ritlecitinib (PF-06651600), which received breakthrough therapy designation for alopecia in 2018 after showing promise in a phase II trial (see Related links), and a gut-selective pan-JAK inhibitor (TD-1473) that demonstrated promising results in early clinical trials and is currently in several phase II/III trials¹⁹³.

BTK inhibitors have been highly successful in the treatment of B cell-related blood cancers (see above), and the role of B cells in autoimmune diseases has also led to BTK inhibitors being investigated for such diseases. Seven BTK inhibitors are being studied in phase II trials for systemic lupus erythematosus, and two BTK inhibitors (evobrutinib and SAR442168) are in phase II and phase III trials for multiple sclerosis, with evobrutinib showing marginal effectiveness with limited toxicities in a previous trial^{194,195}.

As noted above, at least 45 different novel kinase families are being targeted in clinical trials, which include more than 110 different kinases identified as the primary targets. Several families have been targeted by a particularly high number of agents in clinical development, with inhibitors undergoing evolutions of chemical types and targeted indications. Interestingly, novel families in the TK group are less targeted in comparison with the other major kinase groups. In the CMGC


(CDK, MAPK, GSK3 and CLK families) group, nearly 50 agents have entered trials targeting members that have been studied in clinical trials for a long time, such as the mitogen-activated protein kinase (MAPK) p38 family, the ERK family and members of the cyclin-dependent kinase (CDK) family. More than 20 agents have targeted the Aurora kinase family, while in the AGC group, 17 inhibitors have targeted the AKT (protein kinase B, PKB) family. Further details of all targeted families are provided in Supplementary Fig. 1. Selected examples of the novel families are discussed below, subdivided into those that are being investigated for oncology indications and those that are being investigated for indications beyond oncology. FIGURE 7 summarizes the disease indications of kinase-targeted agents in clinical trials.

Investigational kinase inhibitors with novel targets in oncology.


The Aurora kinase family (Aurora kinase A, Aurora kinase B and Aurora kinase C) has been the most targeted kinase family for which an agent has not yet been approved, with 22 agents having entered clinical trials. The role of these kinases in cell division and their overexpression in a broad range of human tumours has long stimulated interest in their potential as therapeutic targets¹⁹⁶, but the development of more than 80% (18) of Aurora kinase inhibitors that have reached clinical trials has been discontinued. First-generation Aurora kinase inhibitors were tested in solid tumours, but results from trials showed limited efficacy and high toxicity, potentially because cell proliferation in solid tumours is relatively slow and drug exposure through a number of cell cycles is needed to induce maximum tumour anti-proliferation effects¹⁹⁷. These clinical disappointments brought a change in strategy, and second-generation, isoform-selective Aurora kinase inhibitors are being investigated for haematological malignancies based on the rationale that they have higher homogeneity and higher proliferation rates relative to solid tumours¹⁹⁷. Currently, four Aurora kinase inhibitors are in trials as monotherapies or in combinations in leukaemias such as acute myeloid leukaemia and chronic lymphocytic leukaemia, and also in solid tumours.

The CDK family includes 20 members, which can be functionally classified into families that act in controlling cell cycle transitions (including CDK1, CDK2, CDK4, CDK5 and CDK6) and regulating transcription (including CDK8, CDK9, CDK11 and CDK20), although both of these activities are present in several family members such as CDK7 (REF.⁶⁶). On the basis of their roles in the control of cell division and that cancers exhibit dysregulation of the cell cycle, CDKs have been therapeutic targets for 20 years. The first-generation CDK inhibitors, such as the extensively studied flavopiridol (alvociclib), which targets most CDKs, showed insufficient efficacy and significant toxicity¹⁹⁸. Development of next-generation inhibitors led to the successful validation of selectively targeting CDK4 and CDK6 for the treatment of breast cancer in 2015 with the FDA approval of palbociclib, followed by abemaciclib and ribociclib in 2017 (see above). Members of the CDK family continue to be intensively investigated in clinical trials, with five novel SMKIs that target the CDK4

a Molecule type



b Ongoing trials and approved agents



◀ Fig. 7 | **Disease indications of kinase-targeting agents in clinical trials.** **a** | Kinase inhibitors in clinical trials. This graph illustrates the number of kinase inhibitors per disease category in clinical trials. The length of the bar is proportional to the number of agents. The colour of the bars and roman numerals correspond to the highest achieved phase by each agent for a particular category of indications. Some agents may belong to several categories simultaneously and have a different highest phase reached for each category. The neoplasms category has a separate scale. Biologics and small molecules are divided into subfigures. For this chart, both active and inactive clinical trials have been included. **b** | Indications in active clinical trials. The pie charts show the distribution of indications in ongoing clinical trials and among approved agents. The colours of the slices correspond to the category of indication.

family in clinical trials, and an additional 12 SMKIs targeting CDK7, CDK8/CDK19, and CDK2 and CDK9 either selectively or in combinations with other agents currently in phase I and II trials.

Tumour cells are known to develop resistance to many cancer therapies via the DNA damage response (DDR), which supports DNA repair¹⁹⁹. Several SMKIs that have been specifically developed to combat this resistance mechanism by targeting kinases involved in the DDR are being investigated in clinical trials, including ataxia-telangiectasia and Rad3 related (ATR), DNA-dependent protein kinase catalytic subunit (DNA-PK) and checkpoint kinase 1 (CHK1)²⁰⁰. Currently, four SMKIs that target ATR, DNA-PK or CHK1 are in 20 phase II trials for different types of malignancy.

Investigational kinase inhibitors with novel targets beyond oncology. Currently, more than 40 kinase inhibitors are in clinical trials for immune system disorders such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis and alopecia areata, with 12 agents in phase III trials. Some of these agents inhibit established targets such as JAKs, as noted above, but there are also novel kinase targets being pursued for inflammatory diseases, including IL-1 receptor-associated kinase 4 (IRAK4), receptor-interacting serine/threonine protein kinase 1 (RIPK1), tumour progression locus 2 (TPL2) and tyrosine kinase 2 (TYK2).

There are currently 16 SMKIs in clinical trials for rheumatoid arthritis. All three of the agents in phase III trials have established targets, but one SMKI in a phase II trial has a novel mode of action: PF-06650833 targets IRAK4, thereby inhibiting signalling by IL-1, which is a potent pro-inflammatory cytokine that is involved in the pathogenesis of various autoimmune diseases²⁰¹.

RIPK1 is important in mediating inflammation by another potent pro-inflammatory cytokine — tumour necrosis factor (TNF) — and increased RIPK1 activity is associated with neuroinflammation and cell necroptosis²⁰². The first agent targeting RIPK1 entered clinical trials in 2015, and there are now three RIPK1 SMKIs in clinical trials. The furthest advanced of these is GSK2982772 (REF.²⁰³), which has completed eight phase I and II clinical trials for the treatment of various autoimmune diseases and is in a phase I trial for moderate to severe psoriasis.

Accumulating evidence has described the multifaceted ways in which TPL2 is involved in inflammation, including positive regulation of MEK1/MEK2 to

activate ERK1/ERK2 signalling²⁰⁴ and positive regulation of p38 α and p38 δ in neutrophils²⁰⁵. Hence, it is speculated that inhibition of its activity may be beneficial in treating inflammatory diseases such as rheumatoid arthritis and psoriasis²⁰⁵ as well as in multiple sclerosis²⁰⁶. One TPL2 inhibitor, GS-4875, has entered clinical trials and is currently in a phase II study for the treatment of ulcerative colitis.

Overall, 15 agents are in clinical trials for the treatment of psoriasis through inhibition of several kinases in addition to RIPK1, including JAK1, TYK2, IRAK4 and ROCK2. Interestingly, JAK kinases (JAK1–3 and TYK2) harbour two kinase domains: a catalytically active JH1 domain and the pseudokinase domain JH2, which has an important role in TYK2 activation. All clinically approved JAK inhibitors are JH1 inhibitors that show moderate selectivity within the JH1 domains, a property that has been linked to serious side effects. The pseudokinase domain of TYK2, however, shows some structural features that have been explored for inhibitor development. The leading agents in this area are the two TYK2 JH2 inhibitors deucravacitinib (BMS-986165) and BMS-986202 (REF.²⁰⁷). These have both been shown to potently prevent TYK2 activation, with remarkable selectivity over other JAK family members and the kinome, and are currently in phase III trials. Adverse events have been reported for deucravacitinib, including accidental eye injury, dizziness and in situ malignant melanoma²⁰⁸, but if these agents prove sufficiently safe and maintain the same effectiveness in current phase III trials, they are likely to be approved in the near future, thereby becoming the first inhibitors that target an inactive pseudokinase domain.

CDC-like kinase 2 (CLK2) and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) are regulators of Wnt signalling, chondrogenesis and inflammation, and inhibiting these kinases has demonstrated potential disease-modifying effects for osteoarthritis²⁰⁹. The small-molecule dual kinase inhibitor lorecivivint has shown promising osteoarthritis therapeutic effects by inducing chondrocyte differentiation, cartilage regeneration and protection, and improving joint health score²¹⁰. It is currently in three phase III trials for treatment of knee osteoarthritis, and results from a phase II trial demonstrate the disease-modifying abilities of lorecivivint and its potential as a first-in-class drug²¹¹.

The p38 MAP kinases were originally discovered as key regulators of inflammatory cytokine biosynthesis²¹² in the 1990s, and they have since been extensively pursued for inflammatory diseases such as rheumatoid arthritis, without any inhibitors directed at these kinases being approved so far. At least 20 such agents have entered clinical trials, but the development of 16 (80%) of these agents seems to have been discontinued. First-generation SMKIs targeted p38 α and p38 β ²¹³, but off-target effects, potency issues, compensatory pathways and toxicity have limited their clinical development²¹⁴. Second-generation inhibitors were developed, such as the slow off-rate inhibitor BIRB 796 (REF.²¹⁵), which have also not been successful²¹⁶. However, a recent review notes a shift in p38 research to focus on more acute inflammatory disorders including chronic obstructive pulmonary disease or asthma²¹⁷. Furthermore, p38 kinase function has been

linked to several neurological and psychiatric disorders, particularly when associated with neuroinflammatory responses²¹⁸. One of the most recent p38 SMKIs to enter clinical trials, neflamapimod (VX-745), is in a novel class of p38 inhibitors that contain a bicyclic heterocycle core with increased selectivity for p38 α over p38 β ²¹⁹. Neflamapimod demonstrated statistically significant cognitive improvements in patients with Alzheimer disease in phase II trials (see Related links), and is currently in three phase II trials for the treatment of Huntington disease (NCT03980938), Alzheimer disease (NCT03435861) and dementia with Lewy bodies (NCT04001517).

Exploration of kinase inhibitors in nervous system disorders is at an early stage, with no approved inhibitors and the majority of drugs still in phase I or II trials. Several agents in addition to neflamapimod are in clinical trials that target various aspects of pro-inflammatory cytokine production and immune response, based on the evidence for the importance of inflammation in disorders such as Alzheimer disease²²⁰. DNL747 inhibits RIPK1, edicotinib (JNJ-40346527) targets colony-stimulating factor 1 receptor (CSF1R), and masitinib binds to KIT and other RTKs. In December 2020, masitinib was reported to provide clinical benefit as an add-on therapy to cholinesterase inhibitors compared with placebo in a phase II/III trial (see Related links), and a confirmatory trial should be initiated soon. Another interesting agent is saracatinib (AZD0530), which inhibits Fyn kinase, a member of the Src family. This may be a promising strategy for Alzheimer disease therapy because its downstream pathway is believed to underlie the toxicity of amyloid- β , a hallmark of the disease²²¹. Interestingly, saracatinib has also been analysed as a potential therapeutic candidate for alcohol use disorder in a phase II trial (NCT02955186) because Fyn signalling is implicated in alcohol drinking behaviour²²².

Another interesting kinase target for nervous system disorders is leucine-rich repeat kinase 2 (LRRK2), as activating mutations in *LRRK2* are the most common autosomal-dominant cause of inherited Parkinson disease^{223,224}. Three LRRK2 inhibitors have now entered phase I trials for the treatment of Parkinson disease: two SMKIs (DNL201 and DNL151) and one antisense oligonucleotide (ION-859). So far, results for DNL201 show that it was well tolerated (see Related links), and DNL151 is scheduled to advance in clinical trials. A trial of ION-859 is currently recruiting patients.

Adaptor-associated kinase 1 (AAK1) is receiving considerable attention as a target for the treatment of neuropathic pain that might provide the basis for a new class of analgesics²²⁵. Studies in animal models showed that inhibition of AAK1 was mechanistically linked to $\alpha 2$ adrenergic signalling rather than opioid receptors to reduce pain responses²²⁵. One novel AAK1 inhibitor has entered trials; the small molecule LX9211 is currently in two phase II trials for neuralgia and diabetic neuropathy and recently received fast-track designation from the FDA (see Related links).

Kinases for which the development of inhibitors has been discontinued. There are at least 11 kinase families and approximately 20 kinase targets for which the

development of inhibitors appears to have stalled or been abandoned, as there are no agents in active trials, and many of the latest status reports from these agents are from more than 5 years ago. The discontinued agents and kinase targets in our dataset are provided in Supplementary Table 4, and we discuss selected examples briefly here.

One important family is the Jun N-terminal kinase (JNK) family, which are MAP kinases involved in regulating cell survival and proliferation in response to cytokines and growth factors that have been implicated in a range of diseases including cancer, immune diseases and neurodegenerative disorders²²⁶. Four JNK inhibitors reached clinical trials for treatment of myeloid leukaemia in 2005 (CC-401; phase I), fibrotic disorders in 2011 (CC-930; phase II), endometriosis in 2012 (PGL5001; phase II) and hearing loss in 2008 (AM-111; phase III trial completed in 2017) but have not progressed further. Common limitations of kinase inhibitors including toxicity and lack of kinase specificity have been cited as probable reasons²²⁷.

A more recent example of a novel kinase target in clinical trials for which drug development appears to be suspended is the monopolar spindle 1 (MPS1) kinase, which has an important role in cell division²²⁸. Two ATP-competitive kinase inhibitors, BAY1161909 and BAY1217389, showed modest efficacy as single agents in preclinical models but synergistic effects in combination with paclitaxel²²⁹ and entered phase I trials in combination with paclitaxel. While the development of BAY1161909 was terminated as a strategic decision, BAY1217389 completed the trial and demonstrated good tolerability with manageable adverse effects and preliminary evidence of efficacy²³⁰, but its development appears to have been recently discontinued.

Outlook

Although there have been substantial advances in kinase drug discovery, there are still many challenges and opportunities in this field. In the oncology area, where kinase inhibitors have become one of the cornerstones of cancer therapy in the two decades since the approval of imatinib, combating drug resistance is imperative for long-term effectiveness, and several such strategies are being developed. The design of drugs that target common and rare kinase driver mutations is one approach being used to combat drug resistance, as illustrated by the development of multiple generations of kinase inhibitors for NSCLC discussed above. The use of combination regimens is another approach, as illustrated by the application of combinations of BRAF and MEK inhibitors in the treatment of melanoma. Furthermore, as multiple kinase inhibitors are being combined to create effective, durable, therapies, rational development of single molecules that inhibit multiple relevant kinases may be another ambitious approach.

There are also several functional challenges such as the characterization of genetic aberrations in the cancer kinome, as well as identification of bona fide drivers responsible for tumour development. A careful analysis of biological pathways for kinases and their relation to cell biology and therapeutic intervention is of high

Box 3 | Probing the kinome with tool compounds

Developing tool compounds to assess the bioactivity and selectivity of kinase inhibitors is particularly important in kinase research owing to the propensity of kinase inhibitors to cross-react with multiple kinases. Tool compounds have been successfully used to create kinase inhibitors for clinical development; for example, a highly potent and monoselective inhibitor for RIPK1 was recently reported (GSK'481)²⁵⁴, which was then optimized into a first-in-class clinical candidate for treatment of inflammatory diseases (GSK2982772) that is currently in clinical trials²⁰³.

We queried ChemicalProbes.org to investigate tool compounds that are publicly available for kinase drug discovery. Results included 85 kinase inhibitors classified as historical compounds; that is, small molecules that are typically non-selective or not sufficiently potent compared with other chemical probes. This means that 35% of their historical compound dataset are kinase inhibitors, which indicates not only the incredible amount of work that has been dedicated to kinase inhibitor development, but also the inherent difficulty in creating selective and potent kinase inhibitors.

Results also included 127 chemical probes, with ten of these compounds currently undergoing curation (Supplementary Table 5). At least 22 probes target unexplored kinases that have not yet reached clinical development as a primary target and at least 56 probes target kinases that are identified as a primary target of a kinase inhibitor in clinical development. This means that more than 75 tool compounds are available to optimize and advance kinase inhibitors in clinical development. Additionally, 49 probes that target already validated kinases were classified.

Aside from tyrosine kinases, tool compounds that target the CDK, MAPK, GSK and CLK (CMGC) families and the 'other kinases' group are the most common. Nearly 40 probes have recent expert review comments posted in 2020, including several that target kinases that have not yet reached clinical trials such as the serine/threonine protein kinases TBK1 and NEK2, mitotic checkpoint serine/threonine protein kinase BUB1 and activated CDC42 kinase 1 (ACK1). These kinases have been identified in diseases that are amenable to kinase inhibition, including neoplasms, skin disorders and neurological disorders such as dementia and amyotrophic lateral sclerosis.

importance, as a kinase might be a tumour suppressor in non-malignant cells yet mediate tumour survival in malignant cells. For example, it has been known for a long time that the ATR–ATM pathway initiates apoptosis following DNA damage, and its impairment leads to tumorigenesis²³¹. However, it was discovered later that this pathway is also exploited by tumour cells to resist the effects of DNA-damaging cancer therapies, and this has led to the development of inhibitors of kinases such as ATR, DNA-PK and CHK1, which are currently in clinical trials (see above).

Our analysis indicates that at least 70% (approximately 400 kinases) of the kinome is still unexplored in drug development in the sense that no agents for which these kinases are considered primary targets have entered clinical trials. Several metrics can provide some indication of the relative levels of exploration of members of the kinase family, including the literature output, the number of compounds that inhibit each kinase in the database ChEMBL and the number of available resolved structures in the Protein Data Bank. An ongoing initiative integrating such knowledge is the NIH Illuminating the Druggable Genome (IDG) project, which collates evidence from multiple domains to map the knowledge gaps around potential drug targets and also prompt investigation into understudied but potentially druggable proteins. IDG presents the information in the user interface Pharos²³² and also highlights interesting understudied targets (see Target Watch in Related links). IDG has classified 635 protein kinases according to different target development levels, and they estimate that 3% (21 kinases; T_{dark}) of the kinome is characterized

as 'dark', where virtually nothing is known about these kinases, and about 30% (188 kinases; T_{bio}) do not have known drug or small-molecule activities that pass their specific activity thresholds, which include scores from text-mining the literature and Gene Reference Into Function annotations. Interestingly, understudied proteins including those identified in T_{dark} and T_{bio} classes may be frequently altered in different types of cancer, indicating their potential functional importance for previously uncharacterized tumour cell phenotypes²³³. Furthermore, in a recent clinical study that assessed transcriptional alterations in triple-negative breast cancer tumours, both T_{dark} and T_{bio} understudied proteins were found to be transcriptionally altered, demonstrating that they are co-regulated transcriptionally with other kinases that have been more investigated (for example, kinases targeted by approved drugs)^{233,234}. This illustrates the potential therapeutic importance of identifying and further investigating these understudied kinases.

Overall, the current state of research on kinases indicates strong publicly available knowledge, with wide structural coverage and also a substantial number of chemical probes available to investigate the kinome (BOX 3). These efforts to elucidate kinase structures, probes and target characterizations, as well as many other aspects of drug discovery, have been facilitated to a large extent by the Structural Genomics Consortium, which is an open collaborative network of scientists and pharmaceutical companies with the focus to provide research output available to the scientific community. To continue to expand kinase drug discovery, there is a need for further development and refinement of efficient compound screening and profiling technologies. In particular, methods that can identify new chemical matter, including natural compounds, need to be addressed. Additionally, there are challenges in obtaining target selectivity to reduce off-target toxicity. The development of inhibitors with different types of binding mode, such as allosteric and covalent inhibitors, and targeted degraders such as PROTACs and molecular glues (FIG. 5), could have a key role in the next two decades of kinase drug discovery.

Data availability

Data are provided in the Supplementary information. Supplementary Table 1 provides information on protein kinase inhibitors approved by selected regulatory agencies (FDA, EMA, NMPA, PMDA and MFDS) and their primary therapeutic targets. Supplementary Table 2 provides information on agents in clinical trials that target protein kinase signalling pathways. Supplementary Table 3 provides success rates of FDA-approved small-molecule kinase inhibitors in clinical trials. Supplementary Table 4 provides information on kinase targets for which modulators in clinical trials are presumed discontinued. Supplementary Table 5 provides information on chemical probes and historical compounds for kinases. Supplementary Fig. 1 provides information on active and not active small-molecule kinase inhibitors targeting established and novel kinases.

Published online 5 August 2021

1. Deribe, Y. L., Pawson, T. & Dikic, I. Post-translational modifications in signal integration. *Nat. Struct. Mol. Biol.* **17**, 666–672 (2010).
2. Ardito, F., Giuliani, M., Perrone, D., Troiano, G. & Lo Muzio, L. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review). *Int. J. Mol. Med.* **40**, 271–280 (2017).
3. Kanev, G. K. et al. The landscape of atypical and eukaryotic protein kinases. *Trends Pharmacol. Sci.* **40**, 818–832 (2019).
4. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. *Science* **298**, 1912–1934 (2002).
5. Parsons, S. J. & Parsons, J. T. Src family kinases, key regulators of signal transduction. *Oncogene* **23**, 7906–7909 (2004).
6. Tamaoki, T. et al. Staurosporine, a potent inhibitor of phospholipid/Ca²⁺ dependent protein kinase. *Biochem. Biophys. Res. Commun.* **135**, 397–402 (1986).
7. Sun, L. et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. *J. Med. Chem.* **41**, 2588–2603 (1998).
8. Barker, A. J. et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. *Bioorg. Med. Chem. Lett.* **11**, 1911–1914 (2001).
9. Zimmermann, J. et al. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). *Arch. Pharm. Wein.* **329**, 371–376 (1996).
10. Heitman, J., Movva, N. R. & Hall, M. N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. *Science* **253**, 905–909 (1991).
11. Kunz, J. et al. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. *Cell* **73**, 585–596 (1993).
12. Brown, E. J. et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. *Nature* **369**, 756–758 (1994).
13. Sabatini, D. M., Erdjument-Bromage, H., Lui, M., Tempst, P. & Snyder, S. H. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. *Cell* **78**, 35–43 (1994).
14. Pfizer. Rapamune (sirolimus) oral solution. Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021083s067,021110s085lbl.pdf (FDA, 2020).
15. Jürg Zimmermann. Interview with Jürg Zimmermann, global head of oncology & exploratory chemistry at Novartis. *Future Med. Chem.* **1**, 1395–1398 (2009).
16. Fabbro, D. in *Inhibitors of Protein Kinases and Protein Phosphates* (eds Pinna, L. A. & Cohen, P. T. W.) 361–389 (Springer, 2005).
17. Zhang, Q., Zheng, P. & Zhu, W. Research progress of small molecule VEGFR/c-met inhibitors as anticancer agents (2016-present). *Molecules* **25**, 2666 (2020).
18. Huang, L., Jiang, S. & Shi, Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). *J. Hematol. Oncol. J. Hematol. Oncol.* **13**, 143 (2020).
19. Wu, P., Nielsen, T. E. & Clausen, M. H. FDA-approved small-molecule kinase inhibitors. *Trends Pharmacol. Sci.* **36**, 422–439 (2015).
20. Wu, P., Nielsen, T. E. & Clausen, M. H. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. *Drug Discov. Today* **21**, 5–10 (2016).
21. Szilveszter, K. P., Németh, T. & Mócsai, A. Tyrosine kinases in autoimmune and inflammatory skin diseases. *Front. Immunol.* **10**, 1862 (2019).
22. Xie, Z., Yang, X., Duan, Y., Han, J. & Liao, C. Small-molecule kinase inhibitors for the treatment of nononcologic diseases. *J. Med. Chem.* **64**, 1283–1345 (2021).
23. Yang, J. et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. *Mol. Cancer* **18**, 26 (2019).
24. Roskoski, R. Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. *Pharmacol. Res.* **103**, 26–48 (2016).
25. Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update. *Pharmacol. Res.* **165**, 105463 (2021).
26. Fabbro, D., Cowan-Jacob, S. W. & Moebitz, H. Ten things you should know about protein kinases: IUPHAR Review 14. *Br. J. Pharmacol.* **172**, 2675–2700 (2015).
27. Fedorov, O., Müller, S. & Knapp, S. The (un)targeted cancer kinome. *Nat. Chem. Biol.* **6**, 166–169 (2010).
28. Roskoski, R. A historical overview of protein kinases and their targeted small molecule inhibitors. *Pharmacol. Res.* **100**, 1–23 (2015).
29. Stransky, N., Cerami, E., Schalm, S., Kim, J. L. & Lengauer, C. The landscape of kinase fusions in cancer. *Nat. Commun.* **5**, 4846 (2014).
30. Lahiry, P., Torkamani, A., Schork, N. J. & Hegele, R. A. Kinase mutations in human disease: interpreting genotype–phenotype relationships. *Nat. Rev. Genet.* **11**, 60–74 (2010).
31. Fleuren, E. D., Zhang, L., Wu, J. & Daly, R. J. The kinome ‘at large’ in cancer. *Nat. Rev. Cancer* **16**, 83–98 (2016).
32. Essegian, D., Khurana, R., Stathias, V. & Schürer, S. C. The clinical kinase index: a method to prioritize understudied kinases as drug targets for the treatment of cancer. *Cell Rep. Med.* **1**, 100128 (2020).
33. Tuna, M., Amos, C. I. & Mills, G. B. Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors. *Oncotarget* **10**, 2095–2111 (2019).
34. Ben-Neriah, Y., Daley, G. Q., Mes-Masson, A. M., Witte, O. N. & Baltimore, D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. *Science* **233**, 212–214 (1986).
35. Jabbour, E. & Kantarjian, H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. *Am. J. Hematol.* **95**, 691–709 (2020).
36. Liu, J. et al. Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation. *Chem. Biol. Drug Des.* **97**, 649–664 (2020).
37. Chen, K.-K., Du, T.-F., Xiong, P.-S., Fan, G.-H. & Yang, W. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia with losing major molecular response as a definition for molecular relapse: a systematic review and meta-analysis. *Front. Oncol.* **9**, 572 (2019).
38. Cerveira, N. et al. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution. *BMC Cancer* **18**, 1245 (2018).
39. American Cancer Society. Lung cancer statistics. How common is lung cancer. <https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html> (2021).
40. de Groot, P. M., Wu, C. C., Carter, B. W. & Munden, R. F. The epidemiology of lung cancer. *Transl Lung Cancer Res.* **7**, 220–233 (2018).
41. Neel, D. S. & Bivona, T. G. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. *NPJ Precis. Oncol.* **1**, 1–6 (2017).
42. Vu, P. & Patel, S. P. Non-small cell lung cancer targetable mutations: present and future. *Precis. Cancer Med.* <https://doi.org/10.21037/pcm.2019.11.03> (2020).
43. Guo, Y. et al. Recent progress in rare oncogenic drivers and targeted therapy for non-small cell lung cancer. *Oncotargets Ther.* **12**, 10343–10360 (2019).
44. Brabender, J. et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. *Clin. Cancer Res.* **7**, 1850–1855 (2001).
45. Ricordel, C., Friboutet, L., Facchinetti, F. & Soria, J.-C. Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer. *Ann. Oncol.* **29**, 128–137 (2018).
46. Gazdar, A. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. *Oncogene* **28**, S24–S31 (2009).
47. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N. Engl. J. Med.* **350**, 2129–2139 (2004).
48. Kuan, F.-C. et al. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. *Br. J. Cancer* **113**, 1519–1528 (2015).
49. Vyse, S. & Huang, P. H. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. *Signal. Transduct. Target. Ther.* **4**, 1–10 (2019).
50. Leonetti, A. et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. *Br. J. Cancer* **121**, 725–737 (2019).
51. Kazandjian, D. et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. *Oncologist* **19**, e5–e11 (2014).
52. Bergeth, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J. Clin. Oncol.* **30**, 863–870 (2012).
53. Gainor, J. F. et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small-cell lung cancer. *JCO Precis. Oncol.* <https://doi.org/10.1200/PO.17.00063> (2017).
54. Della Corte, C. M. et al. Role and targeting of anaplastic lymphoma kinase in cancer. *Mol. Cancer* **17**, 30 (2018).
55. FDA. FDA approves seliparitinib for lung and thyroid cancers with RET gene mutations or fusions. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-seliparitinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions> (2020).
56. FDA. FDA approves pralsetinib for lung cancer with RET gene fusions. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions> (2020).
57. FDA. FDA grants accelerated approval to capmatinib for metastatic non-small cell lung cancer. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-capmatinib-metastatic-non-small-cell-lung-cancer> (2020).
58. FDA. FDA grants accelerated approval to tepotinib for metastatic non-small cell lung cancer. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tepotinib-metastatic-non-small-cell-lung-cancer> (2021).
59. Buti, S., Leonetti, A., Dallatoma, A. & Bersanelli, M. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. *Core Evid.* **11**, 23–36 (2016).
60. Abhinand, C. S., Raju, R., Soumya, S. J., Arya, P. S. & Sudhakaran, P. R. VEGF-A/VEGFR2 signalling network in endothelial cells relevant to angiogenesis. *J. Cell Commun. Signal.* **10**, 347–354 (2016).
61. Dagher, R. et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. *Clin. Cancer Res.* **8**, 3034–3038 (2002).
62. Mei, L. et al. Gastrointestinal stromal tumors: the GIST of precision medicine. *Trends Cancer* **4**, 74–91 (2018).
63. Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. *Lancet Oncol.* **21**, 671–684 (2020).
64. FDA. FDA approves first targeted treatment patients cholangiocarcinoma cancer bile ducts. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-treatment-patients-cholangiocarcinoma-cancer-bile-ducts> (2020).
65. Xuhong, J.-C., Qi, X.-W., Zhang, Y. & Jiang, J. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. *Am. J. Cancer Res.* **9**, 2103–2119 (2019).
66. Sánchez-Martínez, C., Lallena, M. J., Sanfeliciano, S. G. & de Dios, A. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019). *Bioorg. Med. Chem. Lett.* **29**, 126637 (2019).
67. FDA. FDA approves drug to reduce bone marrow suppression caused by chemotherapy. <https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy> (2021).
68. Domingues, B., Lopes, J. M., Soares, P. & Pópulo, H. Melanoma treatment in review. *ImmunoTargets Ther.* **7**, 35–49 (2018).
69. FDA. FDA approves dabrafenib plus trametinib for adjuvant treatment of melanoma with BRAF V600E or V600K mutations. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-plus-trametinib-adjuvant-treatment-melanoma-braf-v600e-or-v600k-mutations> (2018).
70. Yu, C. et al. Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma. *Front. Immunol.* **10**, 990 (2019).
71. Ugurel, S. et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. *Eur. J. Cancer* **83**, 247–257 (2017).
72. Yang, Q., Modi, P., Newcomb, T., Queva, C. & Gandhi, V. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. *Clin. Cancer Res.* **21**, 1537–1542 (2015).

73. Gilead Sciences. ZYDELIG (idelalisib) tablets, for oral use. Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205858s014lbl.pdf (FDA, 2020).
74. FDA. FDA grants accelerated approval to copanlisib for relapsed follicular lymphoma. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-copanlisib-relapsed-follicular-lymphoma> (2017).
75. FDA. duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). <https://www.fda.gov/drugs/resources-information-approved-drugs/duvelisib-copiktra-verastem-inc-adult-patients-relapsed-or-refractory-chronic-lymphocytic-leukemia> (2018).
76. FDA. FDA approves alpelisib for metastatic breast cancer. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-alpelisib-metastatic-breast-cancer> (2019).
77. Burger, J. A. Bruton tyrosine kinase inhibitors: present and future. *Cancer J. Sudbury Mass.* **25**, 386–393 (2019).
78. Looney, A.-M., Nawaz, K. & Webster, R. M. Tumour-agnostic therapies. *Nat. Rev. Drug Discov.* **19**, 383–384 (2020).
79. Martin-Zanca, D., Hughes, S. H. & Barbacid, M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. *Nature* **319**, 743–748 (1986).
80. FDA. FDA approves larotrectinib for solid tumors with NTRK gene fusions. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions> (2019).
81. FDA. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc> (2019).
82. Banerjee, S., Biehl, A., Gadina, M., Hasni, S. & Schwartz, D. M. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. *Drugs* **77**, 521–546 (2017).
83. Zarrin, A. A., Bao, K., Lupardus, P. & Vucic, D. Kinase inhibition in autoimmunity and inflammation. *Nat. Rev. Drug Discov.* **20**, 39–63 (2021).
84. Vainchenker, W. & Constantinescu, S. N. A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. *Hematol. Am. Soc. Hematol. Educ. Program* <https://doi.org/10.1182/asheducation-2005-1.195> (2005).
85. Takada, Y. & Aggarwal, B. B. TNF activates syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF- κ B activation, and apoptosis. *J. Immunol.* **173**, 1066–1077 (2004).
86. Crowley, M. T. et al. A critical role for syk in signal transduction and phagocytosis mediated by Fc γ receptors on macrophages. *J. Exp. Med.* **186**, 1027–1039 (1997).
87. Mócsai, A., Ruland, J. & Tybulewicz, V. L. J. The SYK tyrosine kinase: a crucial player in diverse biological functions. *Nat. Rev. Immunol.* **10**, 387–402 (2010).
88. Mullard, A. FDA approves first-in-class SYK inhibitor. *Nat. Rev. Drug Discov.* **17**, 385–385 (2018).
89. FDA. FDA approves everolimus for tuberous sclerosis complex-associated partial-onset seizures. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-everolimus-tuberous-sclerosis-complex-associated-partial-onset-seizures> (2018).
90. McCormack, P. L. Nintedanib: first global approval. *Drugs* **75**, 129–139 (2015).
91. Kasamon, Y. L. et al. FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis. *Oncologist* **23**, 1511–1519 (2018).
92. Hoy, S. M. Netarsudil ophthalmic solution 0.02%: first global approval. *Drugs* **78**, 389–396 (2018).
93. Smolinski, M. P. et al. Discovery of novel dual mechanism of action src signaling and tubulin polymerization inhibitors (KX2-391 and KX2-361). *J. Med. Chem.* **61**, 4704–4719 (2018).
94. Lombardo, L. J. et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-554825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. *J. Med. Chem.* **47**, 6658–6661 (2004).
95. Motzer, R. J., Hoosen, S., Bello, C. L. & Christensen, J. G. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. *Expert. Opin. Investig. Drugs* **15**, 553–561 (2006).
96. Faivre, S., Demetri, G., Sargent, W. & Raymond, E. Molecular basis for sunitinib efficacy and future clinical development. *Nat. Rev. Drug Discov.* **6**, 734–745 (2007).
97. Cheng, H. & Force, T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? *Prog. Cardiovasc. Dis.* **53**, 114–120 (2010).
98. Odogwu, L. et al. FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations. *Oncologist* **23**, 740–745 (2018).
99. Yu, S. et al. Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. *Exp. Hematol. Oncol.* **6**, 31 (2017).
100. Knighton, D. R. et al. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. *Science* **253**, 414–420 (1991).
101. Knighton, D. R. et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. *Science* **253**, 407–414 (1991).
102. Schindler, T. et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. *Science* **289**, 1938–1942 (2000).
103. Nolen, B., Taylor, S. & Ghosh, G. Regulation of protein kinases: controlling activity through activation segment conformation. *Mol. Cell* **15**, 661–675 (2004).
104. Kornev, A. P., Haste, N. M., Taylor, S. S. & Eyck, L. F. T. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. *Proc. Natl Acad. Sci. USA* **103**, 17783–17788 (2006).
105. Kornev, A. P., Taylor, S. S. & Ten Eyck, L. F. A helix scaffold for the assembly of active protein kinases. *Proc. Natl Acad. Sci. USA* **105**, 14377–14382 (2008).
106. Meharena, H. S. et al. Deciphering the structural basis of eukaryotic protein kinase regulation. *PLoS Biol.* **11**, e1001680 (2013).
107. Fox, T. et al. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase. *Protein Sci. Publ. Protein Soc.* **7**, 2249–2255 (1998).
108. Blencke, S. et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. *Chem. Biol.* **11**, 691–701 (2004).
109. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science* **293**, 876–880 (2001).
110. Rudolf, A. F., Skovgaard, T., Knapp, S., Jensen, L. J. & Berthelsen, J. A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination. *PLOS ONE* **9**, e98800 (2014).
111. Fedorov, O., Niesen, F. H. & Knapp, S. in *Kinase Inhibitors: Methods and Protocols* (ed. Kuster, B.) 109–118 (Humana Press, 2012).
112. Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. *Nat. Biotechnol.* **26**, 127–132 (2008).
113. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. *Nat. Biotechnol.* **25**, 1035–1044 (2007).
114. Drewes, G. & Knapp, S. Chemoproteomics and chemical probes for target discovery. *Trends Biotechnol.* **36**, 1275–1286 (2018).
115. Robers, M. B. et al. Quantifying target occupancy of small molecules within living cells. *Annu. Rev. Biochem.* **89**, 557–581 (2020).
116. Vasta, J. D. et al. Quantitative, wide-spectrum kinase profiling in live cells for assessing the effect of cellular ATP on target engagement. *Cell Chem. Biol.* **25**, 206–214.e11 (2018).
117. Georgi, V. et al. Binding kinetics survey of the drugged kinome. *J. Am. Chem. Soc.* **140**, 15774–15782 (2018).
118. Berger, B.-T. et al. Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2. *Cell Chem. Biol.* <https://doi.org/10.1016/j.chembiol.2021.01.003> (2021).
119. Kanev, G. K., de Graaf, C., Westerman, B. A., de Esch, I. J. P. & Koistra, A. J. KLIFS: an overhaul after the first 5 years of supporting kinase research. *Nucleic Acids Res.* **49**, D562–D569 (2021).
120. Müller, S., Chaikwad, A., Gray, N. S. & Knapp, S. The ins and outs of selective kinase inhibitor development. *Nat. Chem. Biol.* **11**, 818–821 (2015).
121. Guimarães, C. R. W. et al. Understanding the impact of the P-loop conformation on kinase selectivity. *J. Chem. Inf. Model.* **51**, 1199–1204 (2011).
122. Zuccotto, F., Ardini, E., Casale, E. & Angiolini, M. Through the 'gatekeeper door': exploiting the active kinase conformation. *J. Med. Chem.* **53**, 2681–2694 (2010).
123. Waizenegger, I. C. et al. A novel RAF kinase inhibitor with DFG-Out-binding mode: high efficacy in BRAF-mutant tumor xenograft models in the absence of normal tissue hyperproliferation. *Mol. Cancer Ther.* **15**, 354–365 (2016).
124. Wood, E. R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. *Cancer Res.* **64**, 6652–6659 (2004).
125. Axten, J. M. et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). *J. Med. Chem.* **55**, 7193–7207 (2012).
126. Wang, H., Blais, J., Ron, D. & Cardozo, T. Structural determinants of PERK inhibitor potency and selectivity. *Chem. Biol. Drug Des.* **76**, 480–495 (2010).
127. Chaikwad, A. et al. A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. *Nat. Chem. Biol.* **10**, 853–860 (2014).
128. Buchanan, S. G. et al. SCX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. *Mol. Cancer Ther.* **8**, 5181–5190 (2009).
129. Kooistra, A. J. et al. KLIFS: a structural kinase-ligand interaction database. *Nucleic Acids Res.* **44**, D365–D371 (2016).
130. Kohlmann, A., Zhu, X. & Dalgarno, D. Application of MM-GB/SA and watermap to src kinase inhibitor potency prediction. *ACS Med. Chem. Lett.* **3**, 94–99 (2012).
131. Cyphers, S., Ruff, E. F., Behr, J. M., Chodera, J. D. & Levinson, N. M. A water-mediated allosteric network governs activation of Aurora kinase A. *Nat. Chem. Biol.* **13**, 402–408 (2017).
132. Tomita, N. et al. Structure-based discovery of cellular-active allosteric inhibitors of FAK. *Bioorg. Med. Chem. Lett.* **23**, 1779–1785 (2013).
133. Bagal, S. K. et al. Discovery of allosteric, potent, subtype selective, and peripherally restricted TrkA kinase inhibitors. *J. Med. Chem.* **62**, 247–265 (2019).
134. Karpov, A. S. et al. Optimization of a dibenzodiazepine hit to a potent and selective allosteric PAK1 inhibitor. *ACS Med. Chem. Lett.* **6**, 776–781 (2015).
135. Heinrich, T., Grädler, U., Böttcher, H., Blaukat, A. & Shutes, A. Allosteric IGF-1R inhibitors. *ACS Med. Chem. Lett.* **1**, 199–203 (2010).
136. Zhang, J. et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. *Nature* **463**, 501–506 (2010).
137. Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. *Cell* **112**, 859–871 (2003).
138. Hughes, T. P. et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. *N. Engl. J. Med.* **381**, 2315–2326 (2019).
139. Huang, B. X. et al. Identification of 4-phenylquinolin-2(1H)-one as a specific allosteric inhibitor of Akt. *Sci. Rep.* **7**, 11673 (2017).
140. Hirai, H. et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. *Mol. Cancer Ther.* **9**, 1956–1967 (2010).
141. Rettenmaier, T. J. et al. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1. *Proc. Natl Acad. Sci. USA* **111**, 18590–18595 (2014).
142. Jia, Y. et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. *Nature* **534**, 129–132 (2016).
143. Dunto, R. T. & Keating, G. M. Afatinib: first global approval. *Drugs* **73**, 1503–1515 (2013).
144. Serafimova, I. M. et al. Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles. *Nat. Chem. Biol.* **8**, 471–476 (2012).
145. Bradshaw, J. M. et al. Prolonged and tunable residence time using reversible covalent kinase inhibitors. *Nat. Chem. Biol.* **11**, 525–531 (2015).
146. Forster, M. et al. Selective JAK3 inhibitors with a covalent reversible binding mode targeting a new induced fit binding pocket. *Cell Chem. Biol.* **23**, 1335–1340 (2016).

147. Chaikuad, A., Koch, P., Laufer, S. A. & Knapp, S. The cysteineome of protein kinases as a target in drug development. *Angew. Chem. Int. Ed. Engl.* **57**, 4372–4385 (2018).
148. Rao, S. et al. Leveraging compound promiscuity to identify targetable cysteines within the kinome. *Cell Chem. Biol.* **26**, 818–829 (2019).
149. Johnson, T. W. et al. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-[metheno]pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ras oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. *J. Med. Chem.* **57**, 4720–4744 (2014).
150. Bauer, T. M. et al. Brain penetration of lorlatinib: cumulative incidences of CNS and Non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer. *Target. Oncol.* **15**, 55–65 (2020).
151. Zou, H. Y. et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. *Proc. Natl Acad. Sci. USA* **112**, 3493–3498 (2015).
152. Engelhardt, H. et al. Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors. *J. Med. Chem.* **62**, 10272–10293 (2019).
153. Gower, C. M., Chang, M. E. K. & Maly, D. J. Bivalent inhibitors of protein kinases. *Crit. Rev. Biochem. Mol. Biol.* **49**, 102–115 (2014).
154. Cox, K. J., Shomim, C. D. & Ghosh, I. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases. *Future Med. Chem.* **3**, 29–43 (2011).
155. Johnson, T. K. & Soellner, M. B. Bivalent inhibitors of c-Src tyrosine kinase that bind a regulatory domain. *Bioconjug. Chem.* **27**, 1745–1749 (2016).
156. Ekambaram, R. et al. Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1. *ChemMedChem* **8**, 909–913 (2013).
157. Burslem, G. M. & Crews, C. M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. *Cell* **181**, 102–114 (2020).
158. Lai, A. C. & Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. *Nat. Rev. Drug Discov.* **16**, 101–114 (2017).
159. Donovan, K. A. et al. Mapping the degradable kinome provides a resource for expedited degrader development. *Cell* **183**, 1714–1731 (2020).
160. Posternak, G. et al. Functional characterization of a PROTAC directed against BRAF mutant V600E. *Nat. Chem. Biol.* **16**, 1170–1178 (2020).
161. Zhang, X. et al. Design and synthesis of selective degraders of EGFR L858R/T790M mutant. *Eur. J. Med. Chem.* **192**, 112199 (2020).
162. Shah, R. R. et al. Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs. *Bioorg. Med. Chem.* **28**, 115326 (2020).
163. Tinworth, C. P. et al. PROTAC-mediated degradation of Bruton's tyrosine kinase is inhibited by covalent binding. *ACS Chem. Biol.* **14**, 342–347 (2019).
164. Zhang, C. et al. Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK). *Eur. J. Med. Chem.* **151**, 304–314 (2018).
165. You, I. et al. Discovery of an AKT degrader with prolonged inhibition of downstream signaling. *Cell Chem. Biol.* **27**, 66–73 (2020).
166. Brand, M. et al. Homolog-selective degradation as a strategy to probe the function of CDK6 in AML. *Cell Chem. Biol.* **26**, 300–306.e9 (2019).
167. Wei, M. et al. First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo. *Eur. J. Med. Chem.* **209**, 112903 (2021).
168. Robb, C. M. et al. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). *Chem. Commun. Camb. Engl.* **53**, 7577–7580 (2017).
169. Crew, A. P. et al. Identification and characterization of von Hippel-Lindau-recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1. *J. Med. Chem.* **61**, 583–598 (2018).
170. Adhikari, B. et al. PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase. *Nat. Chem. Biol.* **16**, 1179–1188 (2020).
171. Xiang, W. & Wang, S. Selectively targeting tropomyosin receptor kinase (TRKA) via PROTACs. *J. Med. Chem.* **63**, 14560–14561 (2020).
172. Gao, H. et al. Design, synthesis, and evaluation of highly potent FAK-targeting PROTACs. *ACS Med. Chem. Lett.* **11**, 1855–1862 (2020).
173. Mullard, A. First targeted protein degrader hits the clinic. *Nat. Rev. Drug Discov.* **18**, 237–239 (2019).
174. Chen, J., Zheng, X. F., Brown, E. J. & Schreiber, S. L. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. *Proc. Natl Acad. Sci. USA* **92**, 4947–4951 (1995).
175. Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. *Science* **327**, 1345–1350 (2010).
176. Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. *Nat. Chem. Biol.* **14**, 981–987 (2018).
177. Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. *Science* **343**, 301–305 (2014).
178. Petzold, G., Fischer, E. S. & Thomä, N. H. Structural basis of lenalidomide-induced CK1 α degradation by the CRL4(CRBN) ubiquitin ligase. *Nature* **532**, 127–130 (2016).
179. Dubost, C. Primary hyperparathyroidism: the surgical problems. A study of 1,300 operated patients. *Horm. Res.* **32**, 101–103 (1989).
180. Stabicki, M. et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. *Nature* **585**, 293–297 (2020).
181. Rask-Andersen, M., Zhang, J., Fabbro, D. & Schiöth, H. B. Advances in kinase targeting: current clinical use and clinical trials. *Trends Pharmacol. Sci.* **35**, 604–620 (2014).
182. Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. *Nat. Rev. Drug Discov.* **16**, 829–842 (2017).
183. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. *Nat. Biotechnol.* **32**, 40–51 (2014).
184. DiMasi, J. A. & Grabowski, H. G. Economics of new oncology drug development. *J. Clin. Oncol.* **8**, 209–216 (2007).
185. DiMasi, J. A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: success rates for investigational drugs. *Clin. Pharmacol. Ther.* **87**, 272–277 (2010).
186. FDA. Drug development process: clinical research. <https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process> (2019).
187. Walker, I. & Newell, H. Do molecularly targeted agents in oncology have reduced attrition rates? *Nat. Rev. Drug Discov.* **8**, 15–16 (2009).
188. Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. *Drug Discov. Today* **17**, 419–424 (2012).
189. Morgan, P. et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. *Nat. Rev. Drug Discov.* **17**, 167–181 (2018).
190. Venot, Q. et al. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. *Nature* **558**, 540–546 (2018).
191. Hillmann, P. & Fabbro, D. PI3K/mTOR pathway inhibition: opportunities in oncology and rare genetic diseases. *Int. J. Mol. Sci.* **20**, 5792 (2019).
192. Rao, V. K. et al. Effective 'activated PI3K δ syndrome'-targeted therapy with the PI3K δ inhibitor leniolisib. *Blood* **130**, 2307–2316 (2017).
193. Sandborn, W. J. et al. Development of gut-selective pan-Janus kinase inhibitor TD-1473 for ulcerative colitis: a translational medicine programme. *J. Crohns Colitis* **14**, 1202–1213 (2020).
194. Montalban, X. et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. *N. Engl. J. Med.* **380**, 2406–2417 (2019).
195. Haselmayer, P. et al. Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models. *J. Immunol.* **202**, 2888–2906 (2019).
196. Carmena, M., Earnshaw, W. C. & Glover, D. M. The dawn of aurora kinase research: from fly genetics to the clinic. *Front. Cell Dev. Biol.* **3**, 73 (2015).
197. Bavetsias, V. & Linardopoulos, S. Aurora kinase inhibitors: current status and outlook. *Front. Oncol.* **5**, 278 (2015).
198. Asghar, U., Witkiewicz, A. K., Turner, N. C. & Knudsen, E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy. *Nat. Rev. Drug Discov.* **14**, 130–146 (2015).
199. Li, L., Guan, Y., Chen, X., Yang, J. & Cheng, Y. DNA repair pathways in cancer therapy and resistance. *Front. Pharmacol.* **11**, 629266 (2021).
200. Rundle, S., Bradbury, A., Drew, Y. & Curtin, N. J. Targeting the ATR-CHK1 axis in cancer therapy. *Cancers Basel* **9**, 41 (2017).
201. Dinarello, C. A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. *Blood* **117**, 3720–3732 (2011).
202. Degterev, A., O'Fengheim, D. & Yuan, J. Targeting RIPK1 for the treatment of human diseases. *Proc. Natl Acad. Sci. USA* **116**, 9714–9722 (2019).
203. Harris, P. A. et al. Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases. *J. Med. Chem.* **60**, 1247–1261 (2017).
204. Gantke, T., Sriskantharajah, S. & Ley, S. C. Regulation and function of TPL-2, an I κ B kinase-regulated MAP kinase kinase kinase. *Cell Res.* **21**, 131–145 (2011).
205. Senger, K. et al. The kinase TPL2 activates ERK and p38 signaling to promote neutrophilic inflammation. *Sci. Signal.* **10**, eaah4273 (2017).
206. Sriskantharajah, S. et al. Regulation of experimental autoimmune encephalomyelitis by TPL-2 kinase. *J. Immunol.* **192**, 3518–3529 (2014).
207. Liu, C. et al. Discovery of BMS-986202: a clinical Tyk2 inhibitor that binds to Tyk2 JH2. *J. Med. Chem.* **64**, 677–694 (2021).
208. Papp, K. et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. *N. Engl. J. Med.* **379**, 1313–1321 (2018).
209. Deshmukh, V. et al. A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. *Osteoarthr. Cartil.* **26**, 18–27 (2018).
210. Deshmukh, V. et al. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. *Osteoarthr. Cartil.* **27**, 1347–1360 (2019).
211. Yazici, Y. et al. Lorecivint, a novel intraarticular CDC-like kinase 2 and dual-specificity tyrosine phosphorylation-regulated kinase 1A inhibitor and Wnt pathway modulator for the treatment of knee osteoarthritis: a phase II randomized trial. *Arthritis Rheumatism* **72**, 1694–1706 (2020).
212. Lee, J. C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. *Nature* **372**, 739–746 (1994).
213. Scior, T., Domeyer, D. M., Cuanalo-Contreras, K. & Laufer, S. A. Pharmacophore design of p38 α MAP kinase inhibitors with either 2,4,5-trisubstituted or 1,2,4,5-tetrasubstituted imidazole scaffold. *Curr. Med. Chem.* **18**, 1526–1539 (2011).
214. Dambach, D. M. Potential adverse effects associated with inhibition of p38 α/β MAP kinases. *Curr. Top. Med. Chem.* **5**, 929–939 (2005).
215. Regan, J. et al. The kinetics of binding to p38MAP kinase by analogues of BIRB 7936. *Bioorg. Med. Chem. Lett.* **13**, 3101–3104 (2003).
216. Hammaker, D. & Firestein, G. S. "Go upstream, young man": lessons learned from the p38 saga. *Ann. Rheum. Dis.* **69**, i77–i82 (2010).
217. Haller, V., Nahidino, P., Forster, M. & Laufer, S. A. An updated patent review of p38 MAP kinase inhibitors (2014–2019). *Expert Opin. Ther. Pat.* **30**, 453–466 (2020).
218. Asih, P. R. et al. Functions of p38 MAP kinases in the central nervous system. *Front. Mol. Neurosci.* **13**, 570586 (2020).
219. Duffy, J. P. et al. The discovery of VX-745: a novel and selective p38 α kinase inhibitor. *ACS Med. Chem. Lett.* **2**, 758–763 (2011).
220. Heneka, M. T. et al. Neuroinflammation in Alzheimer's disease. *Lancet Neurol.* **14**, 388–405 (2015).
221. Nygaard, H. B. Targeting fyn kinase in Alzheimer's disease. *Biol. Psychiatry* **83**, 369–376 (2018).
222. Ron, D. & Berger, A. Targeting the intracellular signaling 'STOP' and 'GO' pathways for the treatment of alcohol use disorders. *Psychopharmacol. Berl.* **235**, 1727–1743 (2018).
223. West, A. B. et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. *Proc. Natl Acad. Sci. USA* **102**, 16842–16847 (2005).
224. Daher, J. P. L. et al. Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α -synuclein gene-induced neurodegeneration. *J. Biol. Chem.* **290**, 19433–19444 (2015).

225. Kostich, W. et al. Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain. *J. Pharmacol. Exp. Ther.* **358**, 371–386 (2016).
226. Wu, Q. et al. Selective inhibitors for JNK signalling: a potential targeted therapy in cancer. *J. Enzyme Inhib. Med. Chem.* **35**, 574–583 (2020).
227. Messoussi, A. et al. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents. *Chem. Biol.* **21**, 1433–1443 (2014).
228. Liu, X. & Winey, M. The MPS1 family of protein kinases. *Annu. Rev. Biochem.* **81**, 561–585 (2012).
229. Schulze, V. K. et al. Treating cancer by spindle assembly checkpoint abrogation: discovery of two clinical candidates, BAY 1161909 and BAY 1217389, targeting MPS1 kinase. *J. Med. Chem.* **63**, 8025–8042 (2020).
230. Lorusso, P. et al. First-in-human study of the monopolar spindle 1 (Mps1) kinase inhibitor BAY 1161909 in combination with paclitaxel in subjects with advanced malignancies. *Ann. Oncol.* **29**, viii 138 (2018).
231. Pauklin, S., Kristjuhan, A., Maimets, T. & Jaks, V. ARF and ATM/ATR cooperate in p53-mediated apoptosis upon oncogenic stress. *Biochem. Biophys. Res. Commun.* **334**, 386–394 (2005).
232. Sheils, T. K. et al. TCRD and Pharos 2021: mining the human proteome for disease biology. *Nucleic Acids Res.* **49**, D1334–D1346 (2021).
233. Oprea, T. I. et al. Unexplored therapeutic opportunities in the human genome. *Nat. Rev. Drug Discov.* **17**, 317–332 (2018).
234. Zawistowski, J. S. et al. Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex. *Cancer Discov.* **7**, 302–321 (2017).
235. Zheng, J. et al. 2.2 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. *Acta Crystallogr. D Biol. Crystallogr.* **49**, 362–365 (1993).
236. Rask-Andersen, M., Almén, M. S. & Schiöth, H. B. Trends in the exploitation of novel drug targets. *Nat. Rev. Drug Discov.* **10**, 579–590 (2011).
237. Rask-Andersen, M., Masuram, S. & Schiöth, H. B. The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. *Annu. Rev. Pharmacol. Toxicol.* **54**, 9–26 (2014).
238. Attwood, M. M., Rask-Andersen, M. & Schiöth, H. B. Orphan drugs and their impact on pharmaceutical development. *Trends Pharmacol. Sci.* **39**, 525–535 (2018).
239. Kannaiyan, R. & Mahadevan, D. A comprehensive review of protein kinase inhibitors for cancer therapy. *Expert Rev. Anticancer Ther.* **18**, 1249–1270 (2018).
240. Ferguson, F. M. & Gray, N. S. Kinase inhibitors: the road ahead. *Nat. Rev. Drug Discov.* **17**, 353–377 (2018).
241. Ochoa, D. et al. Open Targets Platform: supporting systematic drug–target identification and prioritisation. *Nucleic Acids Res.* **49**, D1302–D1310 (2021).
242. Wishart, D. S. et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Res.* **34**, D668–D672 (2006).
243. Shah, N. P. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. *Cancer Cell* **2**, 117–125 (2002).
244. Gray, N. S. & Fabbro, D. Discovery of allosteric Bcr-Abl inhibitors from phenotypic screen to clinical candidate. *Methods Enzymol.* **548**, 173–188 (2014).
245. Fabbro, D. et al. Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. *Biochim. Biophys. Acta* **1804**, 454–462 (2010).
246. Hantschel, O., Rix, U. & Superti-Furga, G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. *Leuk. Lymphoma* **49**, 615–619 (2008).
247. Manley, P. W. et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. *Biochim. Biophys. Acta* **1804**, 445–453 (2010).
248. Weisberg, E. et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. *Br. J. Cancer* **94**, 1765–1769 (2006).
249. Huang, W. S. et al. Discovery of 3-[2-[imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. *J. Med. Chem.* **53**, 4701–4719 (2010).
250. Adrián, F. J. et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. *Nat. Chem. Biol.* **2**, 95–102 (2006).
251. Wylie, A. A. et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. *Nature* **543**, 733–737 (2017).
252. Schoepfer, J. et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. *J. Med. Chem.* **61**, 8120–8135 (2018).
253. Mauro, M. J. et al. A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with ≥ 2 tyrosine kinase inhibitors (TKIs). *J. Clin. Oncol.* **37**, TPS7070–TPS7070 (2019).
254. Harris, P. A. et al. DNA-encoded library screening identifies benzo[b][1,4]oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors. *J. Med. Chem.* **59**, 2163–2178 (2016).

Acknowledgements

H.B.S. was supported by the Swedish Research Council, the Novo Nordisk Foundation and the Swedish Cancer Foundation. M.M.A. received support from the E. and O. Börjesons Foundation. S.K. acknowledges funding by the SGC, a registered charity that receives funds from AbbVie, Bayer, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genentech, Genome Canada through Ontario Genomics Institute (OGI-196), EU/EFPIA/OICR/McGill/KTH/Diamond, Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (also known as EMD in Canada and the US), Merck & Co. (also known as MSD outside Canada and the USA), Pfizer, São Paulo Research Foundation-FAPESP, Takeda and Wellcome and the Frankfurt Cancer Institute, as well as the German translational cancer network (DKTK). The authors would like to thank E. Faccenda of IUPHAR Guide to Pharmacology for her invaluable help with curating the kinase inhibitors.

Competing interests

D.F. is employed by Cellectia Biotech. Cellectia Biotech had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript or in the decision to publish the results. The other authors declare no competing interests.

Peer review information

Nature Reviews Drug Discovery thanks R. Roskoski, B. Murray and C. Asquith for their contribution to the peer review of this work.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

The online version contains supplementary material available at <https://doi.org/10.1038/s41573-021-00252-y>.

RELATED LINKS

AB Science press release: AB Science communicates the results from the phase 2B/3 study evaluating masitinib in Alzheimer disease: <https://www.ab-science.com/results-from-phase-2b-3-study-evaluating-masitinib-in-alzheimers-disease/>
 Database of FDA-approved drugs: <https://www.accessdata.fda.gov/scripts/cder/daf/>
 Denali press release: Denali Therapeutics announces significant program progress and expected key milestones in 2021 for its broad therapeutic portfolio in neurodegeneration: <https://www.denalitherapeutics.com/investors/press-release?id=7881&type=api>
 EIP Pharma neflamapimod's clinical results release: <https://www.eippharma.com/clinical-results/>
 Gilead press release: Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis: <https://investors.gilead.com/news-releases/news-release-details/gilead-receives-complete-response-letter-filgotinib-treatment>
 IDC and Nature Reviews Drug Discovery Target Watch: <https://commonfund.nih.gov/IDG/NRDD>
 Illuminating the Druggable Genome (IDG) portal: <https://druggablegenome.net/>
 Information regarding clinical trials registered through the U.S.: <https://clinicaltrials.gov/>
 KLIFS: <https://klifs.net/>
 Lexicon press release: Lexicon Pharmaceuticals receives fast track designation from the FDA for LX9211 for diabetic peripheral neuropathic pain: <https://www.lexpharma.com/media-Centre/news/768-lexicon-pharmaceuticals-receives-fast-track-designation-from-the-fda-for-lx9211-for-diabetic-peripheral-neuropathic-pain>
 Pfizer press release: Pfizer receives breakthrough therapy designation from FDA for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with alopecia areata: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_receives_breakthrough_therapy_designation_from_fda_for_pf_06651600_an_oral_jak3_inhibitor_for_the_treatment_of_patients_with_alopecia_areata
 Pharos interface to the Knowledge Management Center for the IDG: <https://pharos.nih.gov/>
 Protein Data Bank (PDB): <https://www.rcsb.org/>
 Resources for tool compounds: <https://www.ebi.ac.uk/chembl/>, <https://pubchem.ncbi.nlm.nih.gov/>, <https://www.guidetopharmacology.org/>, <https://www.chemicalprobes.org/>
 Structural Genomics Consortium (SGC): <https://www.thesgc.org/>
 Weekly updates of clinical developments of drugs: <https://www.centerwatch.com/>

© Springer Nature Limited 2021, corrected publication 2021